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INTRODUCTION 
Cytopenia is a disorder due to decreased production or cessation of one 
or more of the three blood cells[1] . Pancytopenia refers to reduction in all 
three formed elements of blood- erythrocytes, leucocytes and platelets[2]. It  is 
not a disease entity, but rather a triad of findings that may result from a number 
of disease processes.  
Pancytopenia can be a striking feature of many serious and life-
threatening illnesses that may range from simple drug induced bone marrow 
hypoplasia, megaloblastic marrow, hypersplenism to fatal bone marrow 
aplasias and leukemias[3]. Megaloblastic anaemia, either due to Vitamin  
B12 or Folate deficiency, or both, seem to be an important cause in developing 
countries[4,5,6] while aplastic anaemia is a major cause in developed 
nations.[7] 
The incidence of disorders causing pancytopenia varies depending on 
geographic distribution, genetic factors, nutritional status and the prevalence of 
infective disorders. Also the prognosis depends on both, the severity of 
pancytopenia and on the nature of underlying condition[8]. 
Clinically the presenting symptoms are usually attributable to anaemia 
or thrombocytopenia. Leucopenia is not a common cause of initial presentation, 
but can be the most serious threat to life during subsequent course of 
disorder[9,10]. 
2 
 
Careful assessment of the blood film is important if the cause for the 
pancytopenia is not clinically apparent[11]. Physical findings and peripheral 
blood picture provide valuable information in the work up of patients and help 
in planning investigations and the need for bone marrow samples[12] . 
Pancytopenia is an important clinico - haematological entity 
encountered in our day-to-day clinical practice. This study aims to evaluate the 
clinical presentation and etiological spectrum of pancytopenia admitted in our 
tertiary health centre. 
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AIMS AND OBJECTIVES OF THE STUDY 
1) To study clinical profiles of patients with pancytopenia. 
2) To study the underlying etiology of pancytopenia. 
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REVIEW OF LITERATURE 
DEFINITION: 
Pancytopenia is defined as reduction of all the three formed elements of 
blood namely erythrocytes, leucocytes and platelets  below the normal 
reference range[1] . Anaemia is defined as haemoglobin level less than 13g/dl 
in men and 12g/dl in women, according to WHO. Thrombocytopenia is a 
platelet count less than 150,000 per microliter and leucopenia is a white blood 
cell count less than 4,000 per microliter. Although leucopenia may be caused 
by lymphopenia or neutropenia, the most common finding is neutropenia with 
an absolute neutrophil count less than 1,500 per microliter. 
HISTORY OF PANCYTOPENIA: 
Hemopoiesis, the production of blood cells is a fundamental concept in 
haematology. In the eighteenth century, Neumann and Bizzozero established 
the relationship between blood and the bone marrow. In 1868, Neumann noted 
that bone marrow was an important organ for the formation of red blood 
cells[2] . Literature regarding aplastic anaemia and fanconi anaemia are much 
available than various other causes of pancytopenia. In 1888, Dr.Paul Enrilch  
gave the earliest case description of aplastic anaemia where he described a 
young woman who died following an abrupt illness that manifested as severe 
anaemia, bleeding, hyperpyrexia and a markedly hypocellular marrow[13]. In 
1904, the term aplastic anaemia was introduced by Chaufford[13].  Aplastic 
anaemia, a disease due to the absence of hemopoiesis has had a parallel history 
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since the discovery of the function of bone marrow in the mid nineteenth 
century. In 1927, Guido Fanconi first reported Familial syndrome of 
pancytopenia and congenital physical abnormalities. Fanconi described three 
brothers, who had pancytopenia as well as physical abnormalities; he called 
their macrocytic anaemia “perniziosiforme”[1]. Naegeli suggested in 1931 that 
the term Fanconi anaemia be used for familial aplastic anaemia and congenital 
physical anomalies[1] . Environmental influences and nutritional causes of 
pancytopenia were accounted only in the late 20th century. 
STUDIES ON PANCYTOPENIA: 
In literature, various studies are available, that suggests cytopenias as 
manifestations of various systemic disorders. Various studies throughout the 
world have reported the commonest cause of pancytopenia as aplastic anaemia 
[3]. The International Aplastic Anaemia and Agranulocytosis Study(IAAAS) 
conducted a prospective study between 1980 and 1984 in Europe and Israel 
which showed the overall incidence as 2 cases per 1 million people ;however 
the incidence is 3 fold in southeast asia[10].  
In Indian scenario, various studies conducted revealed a nutritional 
disorder, megaloblastic anaemia as the commonest cause of pancytopenia. A 
largest study conducted by Khunger et al included 200 cases of pancytopenia 
and concluded megaloblastic anaemia as the commonest cause which 
accounted to 72%[15]. In another study by Kumar et al done over a period of 6 
years which included 191 cases, megaloblastic anaemia accounted for about 
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39% of cases[12]. Yet, in a recent study by Thilak et al, megaloblastic anaemia 
was proved to be the commonest cause and also revealed few interesting and 
rare causes of pancytopenia like drug induced agranulocytosis, waldenstroms 
macroglobulinemia[3] 
By 1934, aplastic anaemia, although still not clearly defined, was 
described as a distinct clinical entity characterized by pancytopenia and thought 
to be the result of depressed bone marrow activity[1] . A study by Khunger, 
Morley A et al, of lymphocytes from eleven patients with aplastic anaemia, 
suggested that in 7 patients the DNA was abnormal and,it was hence concluded 
that in aplastic anaemia, DNA damage in stem cells may lead to a failure of 
proliferation[15] . In the late 1960s , Mathe et al was among the first to 
postulate an autoimmune basis for aplastic anaemia [16][17]. 
Aplastic anaemia being the most common cause of pancytopenia 
worldwide, many studies are available in the literature accounting for their 
etiology. Idiopathic aplastic anaemia accounts for more than 70% cases of 
paediatric anaemia after ruling out other possible etiology[18]. Also 
Chloramphenicol, a broad spectrum antibiotic introduced in 1949 was also 
found to cause a dose dependent suppression of hemopoiesis, particularly 
erythropoesis, through its action on mitochondrial DNA[19].  
Infective cause of pancytopenia has also been described in a child with 
hereditary spherocytosis who acquired human parvovirus B19 infection 
developed transient pancytopenia[20]. Seronegative hepatitis precedes the 
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diagnosis of aplastic anaemia in 3 to 5% of cases and is recognized as hepatitis 
associated aplastic anaemia[21].  
A Leukemia Research Fund (LRF) -UK based study puts the annual 
incidence of MDS as 3.6 per 100000[22] . One group has suggested a 
prevalance of 1 in 500 in those who presented with pancytopenia[23]. In a 
clinical study in 33 children with primary myelodysplastic syndrome (MDS), it 
was noted that the predominant presenting feature was pancytopenia[24]. 
Also,in a study of the haematological spectrum of myelodysplastic syndrome in 
31 cases, pancytopenia constituted 16.1%[25].  
HEMATOPOIESIS[26] 
This is the process of production of the formed elements of the blood. 
The process takes place in the bone marrow. It initially begins from a single 
type of cell called the pluripotential hematopoietic stem cell, from which all the 
cells of the circulating blood are eventually derived.  
Although these cells reproduce, a small portion of them is retained in the 
bone marrow exactly like the original pluripotential cells but their numbers 
tends to diminish with age. However, most of the reproduced cells differentiate 
to form the other cell types. 
The intermediate stage cells, called committed stem cells become 
committed to a particular line of cells and are very much like the pluripotential 
stem cells.  
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The different committed stem cells, are capable of producing colonies of 
specific types of blood cells when grown in culture. 
A committed stem cell that produces erythrocytes is called a colony-
forming unit–erythrocyte(CFU-E) and those that form granulocytes and 
monocytes have the designation CFU-GM. 
Growth and reproduction of the different stem cells are controlled by 
multiple proteins called growth inducers. Four major growth inducers have 
been described, they promote growth but not differentiation of the cells. 
Interleukin-3, promotes growth and reproduction of virtually all the different 
types of committed stem cells, whereas the others induce growth of only 
specific types of cells. Another set of proteins called differentiation inducer 
causes one type of committed stem cell to differentiate one or more steps 
toward a final adult blood cell. 
Formation of the growth and differentiation inducers in turn is 
controlled by factors outside of the bone marrow. For instance, exposure of the 
blood to low oxygen for a long time results in growth induction, 
differentiation, and production of erythrocytes(RBCs). Similarly, infectious 
diseases cause growth, differentiation, and of specific types of white blood 
cells(WBCs) that are needed to combat infection. 
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Figure: Formation of different blood cells from Pluripotent hematopoietic 
stem cell in the Bone marrow 
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Figure: Genesis of normal Red blood cells. 
 
ETIOLOGY[27] 
Pancytopenia with Hypocellular Bone Marrow  
Acquired aplastic anaemia  
Constitutional aplastic anaemia (Fanconi’s anaemia, dyskeratosis congenita) 
Some of the myelodysplasias  
Rare aleukemic leukemia (AML)  
Some cases of acute lymphoid leukemia  
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Some cases of lymphomas of bone marrow  
Pancytopenia with Cellular Bone Marrow  
Primary bone marrow diseases/disorders  
Myelodysplasia  
Paroxysmal nocturnal hemoglobinuria  
Myelofibrosis  
Some aleukemic leukemia Myelophthisis  
Bone marrow lymphoma  
Hairy cell leukemia  
Secondary to systemic diseases  
Systemic lupus erythematosus  
Hypersplenism  
Vitamin B12, folate deficiency  
Overwhelming infection  
Alcohol  
Brucellosis  
Sarcoidosis  
Tuberculosis  
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Leishmaniasis  
Hypocellular Bone Marrow +/- Cytopenia  
Q fever  
Legionnaires’ disease  
Anorexia nervosa, starvation  
Mycobacteria 
PATHOPHYSIOLOGY OF PANCYTOPENIA: 
There are various mechanisms by which pancytopenia develops. 
1. Conditions associated with a decrease in hematopoietic cell production 
in bone marrow as a result of; 
        a) Destruction of marrow tissue by toxins (acellular or hypoplastic 
marrow).  
              b) Replacement by abnormal or malignant tissue.  
              c) Suppression of normal marrow growth and differentiation.  
      2.   Conditions in which the marrow may be normally cellular or even 
hypercellular, and no abnormal cells may be present. The mechanisms are - 
             a) Ineffective hematopoiesis with cell death in the marrow.  
             b) Formation of defective cells that are rapidly removed from the 
circulation. 
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           c) Trapping of normal cells in hypertrophied and overactive   
reticuloendotheliall system.  
             d) Sequestration and/or destruction of cells by action of antibodies. 
 
CLINICAL FEATURES OF PANCYTOPENIA:  
The clinical manifestations depending on the severity of anaemia, 
leucopenia, and thrombocytopenia[9]. Initial presenting symptoms are usually 
attributable to anaemia and include mild progressive weakness, fatigue and 
exertional dyspnea but symptoms maybe initially subtle hence is neglected by 
the patient. However,elderly patients may present abruptly with heart failure 
symptoms. Those with neutropenia are predisposed to various infections and 
presents with unexplained high fevers, rigor and repeated, persistent infections 
while thrombocytopenia manifest as haemorrhage from skin, nose, and gums. 
Those with severe thrombocytopenia may present with signs and symptoms of 
retinal haemorrhage and even life-threatening intra-cranial bleed. 
A detailed history may shed a light into the etiological diagnosis of 
pancytopenia. History of gastrectomy or ileal resection suggests the possibility 
of vitamin B12 deficiency; history of previous drug intake and cancer therapy 
may suggest drug-induced aplastic anaemia; dark colored early morning urine 
suggests paroxysmal nocturnal hemoglobinuria. Family history may give clue 
to the inherited forms of aplastic anaemias. Personal history like vegan diet, 
alcohol consumption must be entertained and promiscuous behaviour for the 
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possibility of HIV should be enquired. Travel history must also be included to 
rule out infectious causes. 
Physical examination may reveal fever, pallor, 14etechiae and 
ecchymotic patches over the skin, mucous membranes and conjunctiva[9]. 
Presence of splenomegaly and lymphadenopathy should alert the clinician of 
the possibility of leukemia, lymphoma, myelofibrosis and various storage 
diseases. On the other hand, lack of these signs as well as lack of evidence of 
vitamin B12 or folate deficiency should suggest multiple myeloma or aplastic 
anaemia. Diarrhoea, jaundice and weight loss are other possible but rare 
presentation[2]. 
 
MEGALOBLASTIC ANEMIA [27, 28, 29, 30] 
The megaloblastic anaemias are disorders caused by impaired DNA 
synthesis. Those cells having relatively rapid turnover, especially 
hematopoietic precursors and gastrointestinal epithelial cells are primarily 
affected. Eventhough the cell division is sluggish, cytoplasmic development 
progresses normally, so it results in formation of megaloblastic cells which 
tends to be large, with an increased ratio of RNA to DNA . The presence of 
megaloblastic cells is the morphologic hallmark. These megaloblastic erythroid 
progenitors tend to be destroyed in the marrow, a process known ineffective 
erythropoiesis. 
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Megaloblastic anaemia most commonly results from folate or cobalamin 
(vitamin B12 deficiency).  
 
Figure: The role of Folates in DNA synthesis, DHF-Dihydrofolate, GSH-Glutathione 
 
ETIOLOGY OF MEGALOBLASTIC ANAEMIA 
Cobalamine deficiency 
I. Inadequate intake – Vegetarians  
II. Malabsorption  
     A) Defective release of Cobalamin from food 
         1. Gastric achlorhydria  
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         2. Partial gastrectomy  
         3. Drugs that block acid secretion  
     B) Inadequate production of intrinsic factor (IF) 
         1. Pernicious anaemia  
         2. Total Gastrectomy 
         3. Congenital absence or functional abnormality of IF (rare) 
    C) Disorders of terminal ileum  
1. Tropical sprue  
2. Non-tropical sprue  
3. Regional enteritis  
4. Intestinal resection  
5. Neoplasm and granulomatous disorder (rare) 
      D) Competition for Cobalamin  
          1. Fish Tapeworm (Diphyllobothrium latum)  
          2. Bacteria: “blind loop” syndrome  
      E) Drugs: p-amino salicyclic acid, colchicines, neomycin 
III. Others  
     A) Nitrous oxide 
     B) Congential enzyme defect 
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Folic acid deficiency 
I. Inadequate intake: Unbalanced diet (common in alcoholics, teenagers)  
II. Increased requirements  
A) Pregnancy 
    B) Infancy  
    C) Malignancy  
    D) Increased hematopoiesis  
    E) Chronic exfoliative skin disorders 
    F) Hemodialysis 
III. Malabsorption 
     A) Tropical sprue  
B) Non-tropical sprue 
     C) Drugs: Phenytoin, barbiturate, (?) ethanol 
IV. Impaired metabolism  
     A) Inhibitors of dihydrofolate reductase: methotrexate, pyrimethamine, 
triamterene, pentamidine.  
     B) Alcohol 
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Other causes  
I. Drugs that impair DNA metabolism  
   A) Purine antagonists: 6-mercaptopurine , azathioprine, etc.   
   B) Pyrimidine antagonists: 5-flurouracil, cytosine arabinoside etc.  
   C) Others: Procarbazine, hydroxyurea, acyclovir, zidovudin 
II. Metabolic disorders  
    A) Hereditary orotic aciduria  
    B) Lesch-Nyhan syndrome 
III. Megaloblastic anaemia of unknown etiology  
     A) Refractory megaloblastic anaemia  
     B) Di Guglielmos syndrome  
     C) Congenital dyserythropoietic anaemia 
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CLINICAL FEATURES: 
COBALAMIN DEFICIENCY 
Pernicious anaemia (PA) is the most common cause of cobalamin 
deficiency. It  is  a condition in which the portion of gastric mucosa that 
contains the parietal cells is destroyed through an autoimmune mechanism. The 
clinical features of cobalamin deficiency may manifest as hematological, 
gastrointestinal, and the neurological features. The hematologic manifestations 
are almost entirely the result of anaemia and include weakness, light-
headedness, vertigo and tinnitus, as well as palpitation, angina and in severe 
cases, symptoms of congestive failure. Very rarely purpura may appear, due to 
presence of thrombocytopenia. On examination, the patient maybe pale, with 
slight yellowish discoloration of skin and eyes. The gastrointestinal 
manifestations are glossitis in which the tongue appears smooth and beefy red, 
anorexia with moderate weight loss, and diarrhoea.  
Apart from causing megaloblastic anaemia, cobalamin deficiency also 
cause a demyelinating disease, Sub-acute combined degeneration of the spinal 
cord (SACD) that manifests itself as peripheral neuropathy, spastic paralysis 
with ataxia. It may also manifest as dementia, psychosis, or a combination of 
the foregoing. Neurologic symptoms without anaemia as a result of  "Subtle" 
cobalamin deficiency appears to be relatively widespread among the elderly. 
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FOLATE DEFICIENCY 
Folate deficiency most often is nutritional but may also be seen in 
alcoholics, elderly and with patients on hyperalimentation or hemodialysis and 
in malabsorption syndromes such as tropical and nontropical sprue. The 
hematologic and gastrointestinal manifestations are the same as those of 
cobalamin deficiency. However, neurologic abnormalities do not occur. 
Diagnosis is based on serum folate levels, which provides information about 
the current level of folate, and in red cells,the folate levels over the preceeding 
6 weeks. Nutritional folate deficiency is treated with folic acid. 
LABORATORY FEATURES: [27] 
Serum Cobalamin:  
Normal serum levels range from 118-148 pmol/L(160-200ng/L) to ~738 
pmol/L(1000ng/L). In patients with cobalamin deficiency the level is usually 
<74 pmol/L (100ng/L). Values between 74-148 pmol/L (100-200ng/L) are 
considered borderline. 
Serum Folate:  
Normal serum levels range from 11 nmol/L (2 microgram/L) to ~82 
nmol/L (15 microgram/L). It reflects recent diet hence maybe low before there 
is hematologic or biochemical evidence of deficiency. Another valuable 
indicator of body folate stores is the Red cell folate which ranges fron 880-
3520 microMol/L (160-640 microgram/L). 
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Peripheral smear: 
  All cell lines are affected. The blood smear demonstrates marked 
anisocytosis and poikilocytosis, together with macrovalocytes and in severe 
cases can show basophilic stippling and nuclear remnants (Cabot rings, and 
Howell-Jolly bodies). Erythroid activity in the marrow is enhanced, but with a 
decreased reticulocyte count as these megaloblastic cells are usually destroyed 
due to ineffective hematopoiesis. The morphologic changes in the red cells is 
proportional with the severity of anaemia. When the hematocrit is less than 20 
percent, erythroblasts with megaloblastic nuclei, including an occasional 
promegaloblast, may appear in the blood. The presence of megaloblastic cells 
is the morphologic hallmark [mean corpuscular volume (MCV) = 100–150 fl or 
more]. The presence of coexisting iron deficiency, thalassemia trait, or 
inflammation can prevent macrocytosis. Slight macrocytosis often is the 
earliest sign of megaloblastic anaemia. 
  Neutrophils shows hypersegmented nuclei often  more than the usual 
three to five lobes. Cells may contain six or more lobes. In nutritional 
megaloblastic anaemias hypersegmented neutrophils are an early sign of 
megaloblastosis and persist in the blood for many days after treatment. The 
presence of even a single hypersegmented neutrophil should warrant evaluation 
for megaloblastic anaemia. With specific therapy,these abnormalities gets 
corrected usually within 2 days, although some abnormalities may persist for 
months. 
22 
 
 Platelets vary more widely in size (increased platelet distribution width). 
Bizarre and misshapen platelets may also be seen. 
 
 
Figure: Peripheral smear finding of severe megaloblastic anaemia, 
hypersegmented neutrophils. 
Bone Marrow: 
  The bone marrow is hypercellular with a decreased myeloid/erythroid 
ratio which may fall to 1:1 ratio or even lower. Erythroid precursors are 
abnormally large with nuclei that appears much less mature than would be 
expected from the development of the cytoplasm. The nuclear chromatin is 
more dispersed than expected, and it condenses in a peculiar fenestrated 
pattern. Granulocyte precursors are also affected, many being larger than 
normal, including meta-myelocytes. Megakaryocytes are decreased and show 
abnormal morphology. 
23 
 
 
Figure: Bone marrow  finding of severe megaloblastic anaemia 
 
Others : 
  Enhanced intramedullary destruction of erythroblasts results in an 
increase in unconjugated bilirubin and lactic acid dehydrogenase in plasma.  
 Schilling test, although not performed routinely can be used to delineate 
the pathogenesis once cobalamin deficiency has been established.  
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TREATMENT [27] 
  The indications for starting cobalamin therapy are a well-documented 
megaloblastic anaemia or other hematologic abnormalities and neuropathy. 
Replenishment of body stores is achieved with 6 doses IM injection of 1000 
microgram hydroxocobalamin given at 3 to 7 day intervals. A maintenance 
dose is given as 1000 microgram hydroxocobalamin once in every three 
months. 
 In pernicious anaemia, daily dose of 1000-2000 microgram is given 
orally. 
 For folate deficiency, a daily oral dose of 5-15mg folic acid is given and 
continued for about 4 months, when all folate-deficient reds cells would have 
been eliminated and replaced. Cobalamin deficiency should be excluded and 
corrected  before large doses of folic acid are given, as cobalamin neuropathy 
may develop despite correction of anaemia. 
APLASTIC ANEMIA [10] 
Aplastic anaemia is defined as the failure of bone marrow to produce 
blood cell components. 
Pancytopenia with Hypocellular marrow is the Hallmark feature. It is a 
rare entity and is again broadly classified into acquired and inherited cause of 
which the inherited forms are still rarer to encounter. Idiopathic aplastic 
anaemia accounts for approximately 65% of all cases which means that 
majority of cases are without known apparent cause. 
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PATHOPHYSIOLOGY 
The pancytopenia in aplastic anaemia reflects failure/ damage to the 
hematopoietic cell compartment and manifests as a severe decrease in the 
numbers of all hematopoietic progenitor cells. Two mechanisms have been 
suggested for bone marrow failure. Cells bearing the CD34 antigen, which is a 
marker of early hematopoietic cell, are greatly diminished; and committed and 
primitive progenitor cells are virtually absent in functional studies. There are 
two possible proposed mechanism. The first is direct hematopoietic injury by 
chemicals (eg, benzene), drugs, or radiation to both proliferating and quiescent 
hematopoietic cells. The second mechanism, is immune-mediated suppression 
of marrow cells where increased numbers of activated cytotoxic T cells 
observed in aplastic anaemia patients decline with successful immuno-
suppresive therapy. The latter is supported by clinical observations and 
laboratory studies. 
Aplastic anaemia does not appear to result from defective stroma or 
growth factor production. 
CLASSIFICATION OF APLASTIC ANAEMIA[27] 
ACQUIRED 
SECONDARY 
• Drugs and chemicals 
      -Regular effects (Cytotoxic agents, Benzene) 
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      -Idiosyncratic reactions (Chloramphenicol, NSAIDs, Antiepileptics,  
Gold) 
•  Viruses 
       -Ebstein barr virus (infectious mononucleosis) 
       -Hepatitis(non-A,non-B,non-C) 
       -Parvovirus B19 
       -HIV-1 
• Immune diseases 
       -Eosinophilic fasciitis 
       -Hyperimmunoglobulinemia  
       -Large granular lymphocytosis (LGL) 
       -Thymoma / thymic carcinoma 
       -Graft versus Host disease in immunedeficiency 
• Paroxysmal Nocturnal Hemoglobinuria (PNH) 
• Pregnancy  
IDIOPATHIC 
INHERITED 
• Fanconi anaemia 
• Dyskeratosis Congenita 
• Schwachman-Diamond syndrome 
• Reticular dysgenesis 
• Amegakaryocytic thrombocytopenia 
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• Familial Aplastic anaemia 
• Preleukemia (monosomy 7,etc) 
• Non-hematologic syndromes (Down,Dobowitz,Seckel) 
 
CLINICAL FEATURES: 
The onset of illness could be abrupt or have a more insidious course. 
Bleeding is the most common early symptom; the patient would have noticed 
days to weeks of easy bruising, petechiae, gum bleeds, epistaxis, and 
sometimes heavy menstrual flow. Symptoms of anaemia are also frequent, 
including lassitude, weakness, shortness of breath and a pounding sensation in 
the ears. Inspite of decreased white cell count, infection is an unusual first 
symptom. Thorough and detailed history taking is necessary to elicit drug use, 
chemical exposure and preceding viral illness. 
Physical examination may show pallor of the skin and mucous 
membranes which is common. Petechiae and ecchymoses are often present, and 
retinal haemorrhages may be present. A striking feature of aplastic anaemia is 
the restriction of symptoms to the hematologic system; hepatosplenomegaly, 
lymphadenopathy, or bone pain is uncommon. Café au lait spots and short 
stature suggest Fanconi’s anaemia, peculiar nails suggest Dyskeratosis 
congenita. 
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LABORATORY STUDIES 
BLOOD:   
The smear shows large erythrocytes with paucity of platelets and 
granulocytes. Reticulocytes are absent or few, and lymphocyte numbers may be 
normal or reduced.  
Mean corpuscular volume is usually increased. 
BONE MARROW:  
The hallmark of aplastic anaemia is pancytopenia and a hypocellular 
bone marrow. Bone marrow aspiration and biopsy must be performed to rule 
out other possible causes for pancytopenia, such as MDS or leukemia. The 
bone marrow is usually readily aspirated but appears dilute on smear, and the 
fatty biopsy specimen may be grossly pale on withdrawal. The biopsy is 
superior for determination of cellularity and shows mainly fat under the 
microscope, with hematopoietic cells occupying <25% of the marrow space. 
The residual hematopoietic cells have normal morphology except for mild 
megaloblastic erythrocytes. 
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Figure: Bone marrow biopsy of Aplastic anaemia 
ANCILLARY STUDIES:   
Chromosome breakage studies of peripheral blood using 
diepoxybutane[DEB] or mitomycin C should be performed on children to 
exclude Fanconi’s anaemia. Chromosomal studies of bone marrow cells are 
often diagnostic in myelodysplastic syndrome and negative in typical aplastic 
anaemia. Flow cytometric studies is a sensitive test for the diagnosis of PNH. 
Serological studies may show evidence of viral infection, especially Ebstein 
Barr virus and HIV but not for post hepatitis aplastic anaemia which is 
typically seronegative. Also, MRI to assess for marrow fat content can be used 
to differentiate Aplasia from MDS. 
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PROGNOSIS: 
The major prognostic determinant is the blood count. Severe disease is 
defined by the presence of two or three parameters, absolute neutophil count 
<500/microL, platelet count <20,000/microL and corrected reticulocyte count< 
1%. Survival of patients who fulfil these criteria is about 20% at one year after 
diagnosis. 
TREATMENT: 
Treatment aims at reversing the underlying marrow failure and provide 
supportive care. Careful search for correctable cause like exposures to drugs or 
chemicals should be made. Severe acquired aplastic anaemia can be cured by 
replacement of the absent hematopoietic cells by stem cell transplant, or 
ameliorated by suppression of the immune system to allow recovery of the 
patient’s residual bone marrow function. Hematopoietic growth factors have 
limited usefulness and glucocorticoids are of no value as primary therapy.   
Bone marrow transplantation: 
This is the best therapy for the young patient with a fully 
histocompatible sibling donor. For allogenic transplant from fully matched 
siblings, long-term survival rates for children are about 90%. Transplant 
morbidity and mortality are increased among adults, due mainly to the 
increased rate of chronic graft-versus host disease and serious infections. For 
those without a suitable sibling donor, alternative donor transplant is used after 
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high-resolution matching at HLA, conditioning regimens and GVHD 
prophylaxis and has led to improved survival. 
Immunosuppression: 
The standard regimen is the combination of antithymocyte 
globulin(ATG) and cyclosporine. It  induces hematologic recovery in about  
60-70% of patients. The response is better in younger patients compared to 
older ones. 
Horse ATG is given at 40mg/kg per day for four days, rabbit ALG is 
administered at 3.5 mg/kg per day for five days. Most patients are given 
methylprednisolone, 1 mg/kg per day for two weeks, to ameliorate the immune 
consequences of ATG. Cyclosporine is administered orally at an initial dose of 
12 mg/kg per day in adults, with subsequent adjustment according to blood 
levels obtained every two weeks (150-200ng/mL). 
Other therapies:  
The effectiveness of androgen therapy has not been verified in 
controlled trials, but occasional patients showed response on continued therapy. 
For patients with moderate disease or those with severe pancytopenia who have 
failed immunosuppression, a 3 to 4 months trail is appropriate. Hematopoietic 
growth factors, G-CSF, GM-CSF and interleukin-3, are not definite therapy 
and their role is not clear in severe aplastic anaemia. Thrombopoietin mimetics 
by way of acting as a stem cell stimulant has shown blood count recovery in 
refractory cases. 
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Supportive care: 
Most important is the control of infection and in the presence of severe 
neutropenia empiric broad spectrum antibiotic should be promptly initiated 
without waiting for culture reports. 
Both platelet and erythrocyte numbers can be maintained by transfusion. 
Any rational regimen of prophylaxis requires transfusions once or twice weekly 
in order to maintain the platelet count >10,000/microL . Menstruation should 
be suppressed by oral estrogen or nasal LH/FSH antagonists. Red blood cells 
should be transfused to maintain a normal level of activity, usually at a 
hemoglobin value of 7g/dL (9g/dL if there is underlying cardiac or pulmonary 
disease), given as 2 units every 2 weeks (in patient without a functioning bone 
marrow). Iron chelators should be considered at the fiftieth transfusion to avoid 
secondary hemochromatosis. 
HYPERSPLENISM 
The term hypersplenism refers to exaggeration of the spleen's normal 
filtration and phagocytic functions. Hypersplenism usually is characterised by 
triad of splenomegaly, blood cytopenias, and compensatory marrow 
hyperplasia; and these abnormalities are characteristically corrected by 
splenectomy[31]. 
The disorder can occur primarily by enlargement of the spleen from 
vascular congestion, histiophagocytic hyperplasia, cellular infiltration, or 
secondarily by the inability of physically abnormal red cells, such as sickle 
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cells, or antibody-coated cells, such as in immune thrombocytopenia purpura, 
to navigate the circulation or avoid engulfment by the mononuclear phagocyte 
population of the normal spleen[32]. 
Pathophysiology: 
Splenomegaly causes inappropriate sequestration of both normal and 
abnormal blood cells due increase blood channeled through the red 
pulp[33,34]. Spleen enlargement may result from expansion of the red pulp 
compartment in any red cell sequestration process; extramedullary 
hematopoiesis, notably in idiopathic myelofibrosis; hyperplasia or neoplasia 
involving the white pulp, such as infectious mononucleosis or lymphoma, 
respectively; or histiophagocytic hyperplasia. 
The increased size of the filtering bed is more pronounced when the 
splenomegaly is caused by congestion than when it is caused by cellular 
infiltration. Nevertheless, even in these pathologic conditions splenomegaly 
may be associated with severe hypersplenic sequestration of normal cells. 
Splenomegaly increases the vascular surface area and thereby the marginated 
neutrophil pool[35,36]. Platelets are especially likely to be sequestered in an 
enlarged spleen, and up to 90 percent of the total number of platelets in blood 
may be found in massively enlarged spleens. However, sequestered white cells 
and platelets survive in the spleen and may be available when increased 
demand requires neutrophils or platelets, although their release may be 
slow[37]. 
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Red cells are destroyed prematurely in the red pulp and anaemia has 
been considered to be the result of dilution of red cells in an expanded plasma 
volume. However, expansion as measured by radiolabeled albumin or 
fibrinogen, results more from an increase in the splenic pool of protein rather 
an increase in circulating plasma volume. 
Varying amounts of erythrophagocytosis are present, reflecting the 
normal culling of senescent red cells. Erythrophagocytosis increases as a result 
of hemolytic anaemia and viral infections, and in alloimmunized transfusion 
recipients. Macrophages within the sinusoids contain red cell fragments. When 
the process is pronounced, the littoral cells become cuboidal and stand out on 
the basement membrane ("hobnails").  
ETIOLOGY[38] 
Splenomegaly with Appropriate Hypersplenism 
Hereditary hemolytic anemias 
Hereditary spherocytosis 
Hereditary elliptocytosis  
Thalassemia 
Sickle cell anaemia (infants) 
Autoimmune cytopenias  
Idiopathic thrombocytopenia 
35 
 
Essential neutropenia 
Acquired hemolytic anaemia 
Infections and inflammations 
Infectious mononucleosis  
Subacute bacterial endocarditis 
Miliary tuberculosis  
Rheumatoid arthritis (Felty syndrome) 
Lupus erythematosus 
Sarcoidosis  
Brucellosis 
Leishmaniasis 
Schistosomiasis 
Malaria 
Splenomegaly with Inappropriate Hypersplenism 
Congestion (Banti syndrome)  
Cirrhosis of the liver 
Portal vein thrombosis 
Splenic vein obstruction 
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Budd-Chiari syndrome  
Congestive heart failure 
Infiltrative disease 
Leukemias 
Chronic and acute Lymphomas 
Polycythemia vera 
Agnogenic myeloid metaplasia  
Gaucher disease 
Niemann-Pick disease  
Glycogen storage disease 
Amyloidosis 
Laboratory Features: 
The blood cell morphology usually is normal, although a few 
spherocytes may result from metabolic conditioning of red cells during 
repeated slow transits through the expanded red pulp. Reticulocyte count is 
increased due to compensatory increase in red cell production. However, the 
spleen preferentially sequesters reticulocytes hence this finding may be 
quantitatively less evident. There is also a compensatory increase in neutrophil 
or platelet production but is more difficult to identify morphologically. Tests 
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such as epinephrine mobilization have been used to distinguish sequestration 
from ineffective cellular production. Epinephrine releases neutrophils and 
platelets from the spleen, but the test may be difficult to interpret since 
epinephrine also releases the cells from marginal pools[39]. 
Treatment: 
Splenectomy is the mainstay of treatment and produce partial or 
complete recovery of the abnormal blood picture in otherwise uncomplicated 
cases[40]. However, in asymptomatic cases of hypersplenism, splenectomy 
offers no benefit to the patient. Splenectomy is indicated when significant 
problems are caused by the sole or the additional effect of hypersplenism in 
reducing the count of blood cells, usually anaemia of sufficient severity to 
cause symptoms, neutropenia predisposing to infectious, or thrombocytopenia 
causing spontaneous bleeding. 
MYELODYSPLASTIC SYNDROMES [27] 
The myelodysplastic syndromes (MDS) are heterogenous group of 
hematologic disorders broadly characterised by both 1) cytopenias due to bone 
marrow failure and 2) a high risk of development of acute myeloid leukemia 
(AML). Anaemia often with thrombocytopenia and neutropenia occurs with 
dysmorphic and usually cellular bone marrow. 
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Idiopathic MDS is a disease of the elderly with mean age of onset of 
>70yrs with the incidence of 120->500 per million. However, secondary or 
therapy-related MDS is not age related. 
WORLD HEALTH ORGANIZATION(WHO) CLASSIFICATION OF 
MYELODYSPLASTIC SYNDROMES[27] 
1. Refractory cytopenias with unilineage dysplasia (RCUD) 
2. Refractory Anaemia with ringed sideroblasts 
3. Refractory cytopenias with multilineage dysplasia (RMCD) 
4. Refractory Anaemia with excess blasts type-1 (RAEB-1) 
5. Refractory Anaemia with excess blasts type-2 (RAEB-2) 
6. MDS associated with isolated del(5q) 
7. Childhood MDS, including refractory cytopenia of childhood 
8. MDS unclassifiable (MDS-U) 
 
ETIOLOGY AND PATHOPHYSIOLOGY 
MDS is a disease of aging suggesting random cumulative intrinsic and 
environmental damage to marrow cells. It is associated with exposure to 
radiation, benzene,as a late toxicity of cancer treatment usually a combination 
of radiation and radiomimetic alkalyting agents like busulphan, nitrosourea, 
procarbazine or DNA topoisomerase inhibitors. Acquired aplastic anaemias, 
Fanconi anaemia and constitutional marrow failure diseases can evolve into 
MDS. However, typical MDS doesnot seem to have environmental exposures 
or previous hematological illnesses. 
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Pathophysiology has been linked to mutations and chromosome 
abnormalities in some specific MDS syndromes. The 5q- deletion leads to 
heterozygous loss of ribosomal protein gene that is also mutant in Diamond-
Blackfan anaemia, and both are characterised by deficient erythropoiesis. An 
immune pathophysiology may underlie trisomy 8 MDS but the mechanism is 
not clearly understood. 
 
CLINICAL FEATURES 
Most symptoms are that of anaemia and patients complains of gradual 
onset of fatigue and weakness, dyspnea. About one-half of patients are 
asymptomatic and are discovered incidentally on routine blood tests. Fever and 
weight loss are unusual. History should stress on previous chemotherapy and 
radiation exposure. Physical examination is remarkable for signs of anaemia. 
Approximately 20% have splenomegaly. Some unusual skin lesion including 
sweet syndrome occur with MDS. In younger children stereotypical anomalies 
point to a constitutional syndrome. Prognosis strongly correlates with the 
proportion of marrow blasts. 
 
LABORATORY STUDIES 
BLOOD:  
Anaemia is present in most cases. Isolated neutropenia and 
thrombocytopenia is unusual. Macrocytosis is common, but the smear maybe 
dimorphic. Platelets are also large and lack granules. Neutrophils are 
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hypogranulated with hyposegmented, ringed, or contain abnormally segmented 
nuclei; Dohle bodies. Myeloblasts correlates with marrow myeloblasts. 
 
Figure: Peripheral smear of MDS showing hypogranulated eosinophils 
with Pseudo Pelger huet cells (hypolobulated nucleus) 
BONE MARROW:  
Is usually normal or hypercellular but in ~20% is hypocellular. No 
characteristic marrow feature distinguishes MDS but dyserythropoietic changes 
and ringed sideroblasts;hypogranulated and hyposegmented granulocytes, 
increased myeloblasts;reduced number or disorganised nuclei of 
megakaryocytes are commonly observed. Cytogenetics and fluorescent in situ 
hybridisation (FISH) can identify chromosomal abnormalities. 
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TREATMENT:  
Only hematopoietic stem cell transplantation offers cure of MDS. Two 
epigenetic modifiers, Azacitidine and Decitabine have shown to improve 
survival. ATG, cyclosporine and alemtuzumab are effective in younger 
patients. Supportive care plays an important role. 
 
HIV AND THE HEMATOPOIETIC SYSTEM 
Disorders of the hematopoietic system including lymphadenopathy, 
anaemia, leucopenia, and/or thrombocytopenia are common throughout the 
course of HIV infection and may be the direct result of HIV, manifestations of 
secondary infections and neoplasms, or side effects of therapy.[41,42] Direct 
histologic examination and culture of lymph node or bone marrow tissue are 
often diagnostic. A significant percentage of bone marrow aspirates from 
patients with HIV infection have been reported to contain lymphoid aggregates, 
the precise significance of which is unknown. Initiation of HAART lead to 
reversal of most hematologic complications that are the direct result of HIV 
infection[43,44]. 
CAUSES OF BONE MARROW SUPPRESSION IN PATIENTS WITH 
HIV INFECTION 
• HIV infection 
• Mycobacterial infections  
• Fungal infections  
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• B19 parvovirus infection  
• Lymphoma  
• Medications  
o Zidovudine 
o Dapsone 
o Trimethoprim/sulfamethoxazole 
o Pyrimethamine 
o 5-Flucytosine 
o Ganciclovir 
o Interferon-gamma 
o Trimetrexate 
o Foscarnet. 
SYSTEMIC LUPUS ERYTHEMATOSUS 
In patients with SLE apart from antibodies to double strand DNA and 
anti-smith antibodies, antibodies that target each of the cellular blood elements 
are also common; Antierythrocyte and Antiplatelet antibodies against 
erythrocyte membrane and surface and altered cytoplasmic antigens on 
platelets respectively. Antibodies that bind to lymphocytes and neutrophils 
have been described. Anaemia is present in about one-half of patients and is 
multifactorial. It can be associated with a positive Coombs test or 
microangiopathic hemolysis or reflect chronic disease (normochromic, 
normocytic). Leucopenia, particularly lymphopenia, is observed, with the 
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lymphocyte count inversely proportional to the disease activity. An increased 
tendency for lymphocytes to undergo spontaneous apoptosis may contribute to 
lymphopenia. Idiopathic thrombocytopenic purpura can be an early 
manifestation of SLE, and thrombocytopenia can sometimes lead to a life 
threatening haemorrhage[45,46]. 
MALARIA 
 It is a parasitic infection caused by obligate intracellular protozoa of the 
genus Plasmodium[47].Anaemia is the most prominent hematological 
manifestation of malarial infection and is most marked with the species, 
plasmodium falciparum, which invades erythrocytes of all ages. Cellular 
disruption and hemoglobin digestion lead directly to hemolysis. An inadequate 
bone marrow response to anaemia is seen, with relative reticulocytopenia. 
Leucocyte number may be slightly increased or normal; however, leucopenia 
as a result of splenomegaly and impaired marrow function is characteristic. 
Thrombocytopenia is seen in nearly 70% of cases[48]. The effect on the 
hematopoietic system of plasmodium falciparum is similar to that of 
plasmodium vivax not only in the red cell lineage but also in other cell lines, 
characterized by dyserythropoiesis and ineffective erythropoiesis[49]. 
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DENGUE INFECTION 
The hemophagocytic syndrome is an atypical and rare manifestation of 
dengue fever. In the present era, dengue viral infection is leading organism 
responsible for secondary hemophagocytic lymphohistiocytosis (HLH) in 
tropical countries[50,51] 
It has also been described with various infections, malignancy and auto-
immune disorders. HLH is a hyperinflammatory condition which is caused by 
hypercytokinemia due to excessively stimulated but ineffective immune 
response. There is overstimulation of macrophages or monocytes that leads to 
overproduction of various pro-inflammatory cytokines IFN-gamma, TNF-
alpha, IL-6,IL-10 and the macrophage colony stimulating factor. These 
activated cells engulf the red blood cells, white blood cells and thrombocytes 
leading to cytopenia. 
Acquired aplastic anaemia as a result of immune dysregulation triggered 
by dengue virus is one proposed mechanism and there are only few reported 
cases in the literature. The immune response is dominated by oligoclonal 
expanded cytotoxic T calls that targets hematopoietic stem and progenitor cells, 
inducing their cell death via apoptosis and hematopoietic failure[52]. Other 
viruses like Parvovirus B19 and hepatitis also shares the same mechanism. The 
other mechanism in which dengue virus infection causes aplastic anaemia is the 
replication of the virus in the hematopoietic cells, which directly damages these 
hematopoietic cells peripherally or in the bone marrow[53]. 
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MATERIALS AND METHODS 
This study was done at Rajiv Gandhi Government General Hospital, 
Chennai for a period of Six months from August 2017 to January 2018. The 
study was performed after procuring informed written consent from all the 
participants involved. Clearance was obtained from the Ethical Committee of 
Madras Medical College & RGGGH, Chennai. 
 
STUDY DESIGN 
           The study design is a cross sectional study. 
 
POPULATION 
The study population included 100 persons who met the criteria for 
Pancytopenia admitted in the Institute of Internal Medicine, Ragiv Gandhi 
Government General Hospital.  
 
INCLUSION CRITERIA 
1. Age >15years 
2. Anaemia as defined by WHO 
a) <13g/dl in males 
b) <12g/dl in females 
3. Leucopenia [TLC <4000/dl] 
4. Thrombocytopenia [Platelet count <1,50,000] 
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EXCLUSION CRITERIA 
1. Patients who have received or are receiving cancer chemotherapy. 
2. Patients who have received or are receiving cancer Radiotherapy. 
3. Patients who received blood transfusion. 
4. Not given consent for the study. 
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METHODOLOGY 
After obtaining clearance and approval from the institutional ethics 
committee and written informed consent from the patients admitted to RGGGH 
with pancytopenia  who have met both the inclusion and exclusion criteria, 
they were subjected to detailed history taking including the  presenting 
complaints, fever, bleeding manifestations, dietary history, alcohol, smoking or 
other addictions and meticulous physical examination including pallor, icterus, 
hepatomegaly, splenomegaly, lymphadenopathy and bony tenderness. Blood 
samples were collected for complete blood counts including hemoglobin, total 
leucocyte count, platelete count and various parameters such as PCV, MCV, 
MCH, MCHC, peripheral smear examination and LFT. Also Viral markers 
such as HBsAg and Anti-HCV and HIV serology, ultrasound abdomen and 
Chest Xray was done for all patients. Patients with history of fever were 
subjected to fever profile including peripheral smear for Mp,Mf, dengue and 
MSAT test. Vitamin B12 and Folate assay, upper GI endoscopy, thyroid 
function test, ANA profile was done whenever required. Bone marrow study 
was done for selected number of patients when the diagnosis was in doubt. 
STATISTICAL ANALYSIS: Data analysis was done with using the 
statistical analysis SPSS, version 13 software. 
FINANCIAL SUPPORT  :  Nil  
CONFLICTS OF INTEREST :  None 
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OBSERVATIONS AND RESULTS 
DEMOGRAPHICS 
TABLE 1.1: Distribution of pancytopenia according to sex. 
Sex Frequency 
Males 57 
Females 43 
TOTAL 100 
 
 
Figure 1.1: Distribution of pancytopenia according to sex 
 
In our study, out of 100 patients 57% were males and 43% were 
females. 
 
57%
43 %
MALES
FEMALES
49 
 
 
TABLE 1.2: Age & sex wise distribution of pancytopenia. 
Age Male Female Total 
<20 8 3 11 
21-30 10 8 18 
31-40 15 10 25 
41-50 13 8 21 
>50 11 14 25 
TOTAL 57 43 100 
 
 
Figure 1.2 : Distribution of pancytopenia according to age & sex. 
 
The mean age of patients presented with pancytopenia in our study was 
40 years with a standard deviation of 14 years. 
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Mean age for males were 38.4 years and that for females were 42.3 years. 
Maximum number of cases was seen in age group of 31-40 years & > 50 
years  with a combined percentage of 50. 
Amongst males, the maximum number of cases were in age group of 31-
40 years with p-value 0.55 which is not statistically significant. 
Amongst females the maximum number of cases were in age group of 
>50 years with p-value of 0.55 which is also not statistically significant. 
 
  
 SYMPTOMS AT PRESENTATION
TABLE 2.1: Frequency
S.no 
1. Easy fatiguability
2. 
3. Bleeding tendency
4. 
5. 
6. 
7. 
8. 
 
Figure 2.1: Bar diagram showing frequency of 
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CLINICAL FEATURES 
 
 of symptoms associated with pancytopenia.
Symptoms Frequency
 91
Fever 57
 37
Bone pain 6 
Night sweats 7 
Weight loss 32
Anorexia 60
Dyspnea 52
symptoms of pancyt
OF SYMPTOMS
 
 
 
 
 
 
 
 
 
openia. 
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Symptoms of anemia such as easy fatigueability and dyspnea was seen 
in 91% and 52% of patients respectively. 
Fever was present in more than half of the patients at presentation. 
Bleeding manifestation was present in 35% of patients. 
 
Figure 2.2: Frequency of various bleeding manifestation. 
 
Malena was the major bleeding manifestation in our study and was 
present in 15 patients and most of the cases had esophageal varices. 
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MANIFESTATION
 TABLE 2.2: Physical exam
S.no Clinical findings
1. 
2. 
3. 
4. 
5. Lymphadenopathy
6. Sternal tenderness
7. Gum hypertrophy
Figure 2.3 : Bar diagram showing physical examination findings.
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ination findings of pancytopenia
 Frequency
Palor 97
Icterus 11
Hepatomegaly 15
Splenomegaly 27
 3
 5
 2
 
 
11
15
27
3 5
PHYSICAL FINDINGS
 patients. 
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Pallor was seen in 97% of patients and it correlated well with anaemia 
symptoms at presentation. 
Icterus was seen in 11% of patients and most of them had chronic liver 
disease. 
27% of patients had splenomegaly and was seen in all cases of 
hypersplenism and ALL. Some cases of megaloblastic anaemia(21%) and  
MDS(25%) also had splenomegaly. 
Hepatomegaly was present in 15% of patients with pancytopenia and 
majority of them had megaloblastic anaemia and acute leukemia. 
Lymphadenopathy was found in 3% of patients and all the patients had 
acute leukemia. 
Sternal tenderness 5% and gum hypertrophy 2% were exclusively found 
in acute leukemia. 
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INVESTIGATIONS 
TABLE 3.1 : Hematologic parameters in pancytopenia. 
S.no Investigation Frequency 
1. Hb 
<5 40 
5-8 34 
>8 26 
 
S.no Investigation Frequency 
2. TLC 
<1000 5 
1001-2500 38 
>2500 57 
 
S.no Investigation Frequency 
3. Platelets 
<50000 55 
50001-80000 22 
>80000 23 
 
S.no Investigation Frequency 
4. 
Reticulocyte 
count 
<0.5 25 
0.6-1 32 
>1 43 
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Hemoglobin percentage: 
40% of patients had haemoglobin <5g/dl, 34% in the range 5-8g/dl and  
26% of patients had >8g/dl. 
Total leucocyte count: 
More than half of the patients 57% had TLC of 2500-3900 cells/mm3, 
38% of the cases were in the range of 1001-2500 cells/mm3 and 5% of the 
cases had <1000 cells/mm3 
Platelets:  
More than half of the patients had platelet count of <50000 cells/mm3,  
22% of the cases were in the range of 50001-80000 cells/mm3 and 23% had 
>80000 cells/mm3 
Reticulocyte count: 
25% of the patients had reticulocye count of <0.5, 32% of the patients 
had their reticulocyte count in the range of 0.6-1 and most of the cases had their 
reticulocyte count >1 (43%). 
T-TEST FOR HEMATOLOGICAL PARAMETERS AND CLINICAL 
PRESENTATION 
a. TLC count and occurrence of fever 0.055 (not significant) 
b. Platelet  count and occurrence of bleeding manifestation 0.88  
(Not significant) 
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c. Hemoglobin count and occurrence of easy fatigueability 0.8 (not 
significant) or dyspnea 0.73 (Not significant) 
TABLE 3.2 : Peripheral smear study 
S.no Peripheral smear findings Frequency 
1. MCHA 48 
2. NCNC 24 
3. Macrocytes 29 
4. Anisopoikilocytosis 39 
5. Lymphocytosis 9 
6. Immature blast 5 
7. Hypersegmented neutrophils 26 
8. Erythroblast 7 
9. Leucopenia 42 
10. TCP 69 
 
 
Figure 3.1 : Bar diagram of peripheral smear findings.TCP-
thrombocytopenia, NCNC-normocytic normochromic anaemia,MCHA-
microcytic hypochromic anaemia  
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More than half of the patients had thrombocytopenia (69%) and were 
present in clumps. 
Majority of the patients had microcytic hypochromic anaemia (48%) 
and anisopoikilocytosis (39%). Macrocytes  was present in 30% and 
hypersegmented neutrophils in 26% of patients and almost all of them had 
megaloblastic anaemia. Rest of the patients had normocytic norchromic 
anaemia in 24%. 
Leucopenia was present in 42% of patients. Immature blasts in 5% of 
patients and exclusively found in leukemia patients. Lymphocytosis was found 
in 9% of patients and most of them had dengue positive or other viral infection. 
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VARIOUS ETIOLOGIES OF PANCYTOPENIA AND 
THEIR DISTRIBUTION 
TABLE 4.1 : Etiology of pancytopenia. 
Sl. No Etiology Frequency 
1. Megaloblastic Anaemia 37 
2. Aplastic Anaemia 24 
3. Hypersplenism 13 
4. MDS 6 
5. CTD 3 
6. Dengue 4 
7. Malaria 4 
8. ALL 2 
9. AML 3 
10. HIV 1 
11. Disseminated TB 1 
12. Viral Induced 2 
 TOTAL 100 
 
 
Figure 4.1 : Bar chart showing various etiologies of Pancytopenia. 
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More than half of the cases (61%) was diagnosed to have either 
megaloblastic anaemia or aplastic anaemia. 
Megaloblastic  anaemia was found to be the most common cause of 
pancytopenia and was found in 37% of patients. The second most common 
cause was aplastic anaemia and was found in 24% of patients. 
Hypersplenism was diagnosed in 13% of patients and MDS in 6%. The 
other etiologies of pancytopenia were MDS (6%), connective tissue disorders 
such as SLE (3%), infections such as dengue(4%), malaria(4%), disseminated 
TB(1%), HIV(1%) and other viral induced(2%). 
Acute leukemias were diagnosed in 5% of patients(ALL & AML). 
TABLE 4.2: Age wise distribution of various etiology of 
pancytopenia. 
Age 
<20 21-30 31-40 41-50 >50 Diagnosis 
Megaloblastic anaemia 3 5 12 11 6 
Aplastic anaemia 5 3 3 2 11 
Hypersplenism 0 2 4 6 1 
MDS 0 1 0 0 5 
CTD 0 2 1 0 0 
Dengue 0 2 2 0 0 
Malaria 1 1 1 1 0 
ALL 1 0 0 1 0 
AML 1 0 1 1 0 
Disseminated TB 0 0 1 0 0 
Viral induced 0 2 0 0 0 
HIV 0 0 0 0 1 
TOTAL 11 18 25 21 25 
 
 Figure 4.2: Bar chart showing the age
etiologies of Pancytopenia. ALL
acute myeloid leukemia, CTD
myelodysplastic syndrome, HIV
tuberculosis. 
 
Overall, the pancytopenia 
group of 31-40 years and >50years 
50%. 
Most common etiology in various age groups:
In age group <20 years, aplastic an
45.4%. 
Age group 21
aplastic anaemia (16.6%)
0
2
4
6
8
10
12
61 
-wise distribution on various 
-acute lymphoblastic leukemia, AML
- connective tissue disorder, MDS
-human immunodeficiency Virus, TB
cases was found to be more common in age 
age group with a combined percentage of 
 
aemia was found to be more common 
-30 years, megaloblastic anaemia (27.7%) followed by 
 were more common. 
 
-
-
-
<20
21-30
31-40
41-50
>50
62 
 
Age group 31-40 years, megaloblastic anaemia was found to be more 
common (48%).  
Age group 41-50 years, megaloblastic anaemia was again found to be 
more common (52%). 
Age group > 50 years, aplastic anaemia was found to be more common 
(44%).  
TABLE 4.3: Sex wise distribution of pancytopenia on various 
etiologies. 
DIAGNOSIS MALE FEMALE M:F 
Megaloblastic anaemia 21 16 1.3:1 
Aplastic anaemia 13 11 1.2:1 
Hypersplenism 8 5 1.6:1 
MDS 4 2 2:1 
CTD 1 2 0.5:1 
Dengue 2 2 1:1 
Malaria 3 1 3:1 
ALL 1 1 1:1 
AML 1 2 0.5:1 
Viral induced 1 1 1:1 
Disseminated TB 1 0  
HIV 1 0  
TOTAL 57 43 1.3:1 
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Figure 4.3: Bar chart showing Sex wise distribution on various  
etiology of pancytopenia. 
In Myelodysplastic syndrome and Connective tissue disorder, females 
were found to be more common with a male:female ratio of 0.5:1. 
While megaloblastic anaemia, aplastic anaemia and hypersplenism 
were more common in males. 
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IMAGING 
Ultrasound abdomen was done for all patients. 
 
Figure 4.4 : Figure showing USG findings.CLD-chronic liver disease, 
HSM- hepatosplenomegaly, USG- ultrasound. 
Splenomegaly alone was  the most common finding(20) and most of the 
patients had megaloblastic anaemia, hypersplenism or acute leukemia. 
Hepatosplenomegaly was found in 11 patients, CLD in 8 patients and Fatty 
liver was seen in 3 patients, in the latter three, all the patients were found to be 
alcoholic. 
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MEGALOBLASTIC ANAEMIA 
Megaloblastic anaemia was found to be the most common etiology for 
pancytopenia in our study and was found in 37% of cases with a slight male 
preponderance in the ratio  of 1.3:1. 
The mean age for megaloblastic anaemia was 39.8 years with a range of 
17-60 years. 
FIGURE 5.1 : Pie-chart showing sex-wise distribution of patients. 
 
Of the 37 megaloblastic anaemia in our study, 58% of cases were males 
and 42%  were females. 
Male, 58 %
Female, 42 %
 FIGURE 5.2 : B
Almost all patients of megaloblastic an
fatigueability (100%). Fever was the next common presenting 
(48.6%) and 13.5% of these patients had some bleeding manifestation.
On examination, splenomegaly was present in 9 patients (24.3%) and 
hepatomegaly was present in 8 patients (21.6%) 
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FIGURE 5.3: Pie-chart showing frequency of megaloblastic anaemia 
with dietary habits. 
 
29.7% of the patients with megaloblastic anaemia were found to 
consume pure vegetarian diet. 
FIGURE 5.4: Pie-chart depicting the relationship of alcohol and 
smoking with megaloblastic anaemia. 
 
42% of megaloblastic anaemia cases were either alcoholic or smoker or both. 
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FIGURE 5.5 : Bar diagram showing various co-morbidities and their 
frequencies. 
. CLD-chronic liver disease, PHT-portal  hypertension, SHT- systemic hypertension. 
Subclinical hypothyroid, hypothyroid, hyperthyroid and CLD were seen 
in 5 patients which are important cause of megaloblastic anaemia. 
FIGURE 5.6 : Pie-chart showing frequency of macrocytosis in 
patients with megaloblastic anaemia. 
 
76% of the patients showed macrocytosis in blood picture with MCV>100. 
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TABLE 5.1: Showing various blood parameters in megaloblastic 
anaemia. 
Variable Hb g/dl TLC Platelete 
Mean 6.2 2775 2775 
Median 5.5 2900 2900 
Range 2.8-12 500-3900 500-3900 
SD(standard deviation) 2.7 798 798 
 
FIGURE 5.7 : Pie-charting showing the frequency of raised LDH in 
megaloblastic anaemia. 
 
74% of patients had LDH of >500. 
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TABLE 5.5: Peripheral smear findings in megaloblastic anaemia. 
 
MCHA – Microcytic Hypochromic Anaemia 
Anisopoikilocytosis(78.3%), hypersegmented neutrophils(67.5%) and 
macrocytes(62.1%) were the predominant peripheral smear finding for 
megaloblastic anaemia. 
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Most of the patients with megaloblastic an
deficiency alone, 22 out of 37 patients (59.4%). 7 of them had 
deficiency alone (18.9%) and 6 of them had both Vitamin B12 and folate 
deficiency (16.2%). In the latter group, most of them were pure vegeterians. 
Hypothyroidism was seen in 2 patients which was attributable to megaloblastic 
anaemia. 
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Aplastic anaemia was found to be the second most common cause of 
pancytopenia in our study (24) with a male to female ratio of 1.1:1. 
Fanconi anaemia was diagnosed in 1 female patient and a case of 
Toulene induced aplasia was diagnosed in 1 male patient. 
The overall incidence of aplastic anaemia was predominantly found in 
two age groups >50 years (45.8%) and <20 years (20.8%). 
The most common peripheral smear finding of aplastic anaemia was 
MCHA (91.7%) and leucopenia (79.2%) 
FIGURE 6.1: Pie-chart showing sex-wise distribution among patients 
with aplastic anaemia. 
 
Of the 24 cases, males comprised of 54% and females comprised of 
46%. 
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FIGURE 6.2 : Bar diagram showing clinical features of aplastic 
anaemia. 
 
Most of them had symptoms of anaemia such as easy fatigueability 
(87.5%) and dyspnea at presentation. Bleeding manifestation (58.3%) and fever 
(54.1%) was another major complaints that the patient got admitted with. 
HYPERSPLENISM 
Hypersplenism was diagnosed in 13 cases. 
The mean age for hypersplenism was 40.6 years with a male to  female 
ratio of 1.6:1 
In almost all patients spleen was palpable (92.3%) on examination. 
The most common peripheral smear finding of hypersplenism were 
MCHA (92.3%) and reticulocytosis(30.8%). 
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FIGURE 7.1: Sex wise distribution of hypersplenism. 
 
Males comprised of 66.6% and females comprised of 33.4%. 
FIGURE 7.2 : Pie-chart depicting the frequency of  various 
etiological factors of hypersplenism. 
 
CLD- chronic liver disease, EHPVO- Extra hepatic portal vein obstruction, 
NCPF- Non cirrhotic portal fibrosis. 
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CLD with portal hypertension was the most common cause(59%) 
followed by EHPVO, which was seen in 17% of patients. NCPF was another 
cause(8%) and were all female patients. 
CONNECTION TISSUE DISEASE 
SLE was diagnosed in  3 cases of pancytopenia out of which 2 were 
female and 1 was a male patient. 
ACUTE LEUKEMIA 
Acute myeloid leukemia comprised of 3 cases out of which 2 were 
female and 1 male, while Acute lymphoblastic leukemia comprised of 2 cases, 
1 male and 1 female. 
DENGUE  
4 cases of dengue was diagnosed out of which 2 were male and 2 
female. All  of them presented with some form of bleeding manifestation. 
MALARIA 
Malaria was diagnosed in 4 cases of patients in our study, 3 males and 1 
female. All of the patients was diagnosed to have plasmodium vivax malaria. 
VIRAL INDUCED PANCYTOPENIA 
2 cases was diagnosed as viral induced pancytopenia, 1 male and 1 
female. 
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DISSEMINATED TB 
1 male patient had disseminated TB. 
HIV 
1 male patients was diagnosed to have HIV. 
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DISCUSSION 
Pancytopenia is not an uncommon hematological problem that we face 
in our daily practise. It is not a disease per se but rather a triad of findings that 
consists of anaemia, leucopenia and thrombocytopenia. Peripheral 
pancytopenia can be caused by a wide variety of conditions that primarily or 
secondarily affect the bone marrow. The incidence and prevalence of these  
various etiologies depend on a number of factors like the geographic location, 
population groups, nutritional status, exposure to drugs etc.  
In our study, 100 patients were studied and evaluated for various 
etiologies and their clinical presentation. The age group varied from 15-70 
years, with a mean age of 40 years. 
Figure 8.1: Comparison in age group with other studies  
and present study. 
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Males were found to have a slight preponderance in the incidence of 
pancytopenia in our study with a male to female ratio of 1.3:1 which is 
comparable to other studies described below. 
Figure 8.1: Comparison of male to female ratio with other studies. 
STUDY AUTHOR MALE:FEMALE RATIO 
Savage PG et al[54] 1.3:1 
Kumar et al[11] 2.1:1 
Gayathri et al[55] 1.2:1 
Khunger et al[15] 1.2:1 
Kodke et al 1.3:1 
Present study 1.3:1 
 
In our study, the most common etiology was megaloblastic anaemia 
(37%) followed by aplastic anaemia(24%), hypersplenism(12%) and 
myelodysplastic syndrome(6%). 
A comparison of studies  between southern, northern, western and 
eastern India on the  four most common etiology of pancytopenia is described 
below. 
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TABLE 8.2: Comparison of studies in dIfferent region of India on 
most common etiology. 
Author Region Year 1st Common 2nd Common 3rd Common 4
th 
Common 
Dubey et 
al [60] 
(n=248) 
Central 
India, 
MP 
2015 Megaloblastic 
anaemia(41.4%) 
Aplastic 
anaemia(22.9) 
Hypersplenism 
(12.9%) 
AML 
(2.4%) 
Vaddatti 
Tejeswini 
et al [65] 
(n=75) 
South 
India, 
AP 
2015 Megaloblastic 
anaemia (68%) 
Aplastic 
anaemia 
(13.3%) 
Leukemia & 
MDS (both 
5.34%) 
ITP (4%) 
Neha 
Sharma 
et al [56] 
(n=100) 
Jammu 
& 
kashmir 
2017 Megaloblastic 
anaemia (60%) 
Aplastic 
anaemia 
(16%) 
ALL (11%) AML(4%) 
Dasgupta 
et al [66] 
(n=70) 
East 
India, 
WB 
2018 
Aplastic 
anaemia 
(33.4%) 
Megaloblastic 
anaemia 
(20.9%) 
Kala azar 
(13.7%) 
TB 
(4.8%) 
Patel et al 
[67] 
(n=50) 
West 
India, 
Gujarat 
2017 Megaloblastic 
anaemia (58%) 
Aplastic 
anaemia 
(12%) 
Hypersplenism 
(8%) 
Leukemia 
(6%) 
Current 
study 
(n=100) 
South 
India, 
TN 
2018 Megaloblastic 
anaemia (37%) 
Aplastic 
anaemia 
(24%) 
Hypersplenism 
(13%) 
MDS 
(6%) 
ALL- acute lymphoblastic leukemia, AML- acute myeloid leukemia, AP-andhra 
Pradesh,MDS- myelodysplastic syndrome, MP-madhya Pradesh, TB-tuberculosis, WB- west 
Bengal. 
 
The most common symptom at presentation in our study was easy 
fatigueability (91%) followed by anorexia(60%), Fever(57%) and bleeding 
manifestation (37%). Similar results were observed in studies described below. 
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TABLE 8.3: Comparison of studies on most common symptoms at 
presentation. 
Study Easy fatigue % 
Dypnea 
% 
 
Fever 
% 
Bleed 
% 
Pereira & Dias 
et al [61] (n=80) 37.5 30 35 15 
Reddy GP et al 
[63] (n=42) 26.2 59.5 45.2 7.1 
Gayathri et al 
[55] (n=104) 100 43.2 38.4 3.84 
Majed momin et 
al [62] (n=150) 54 24.6 68.6 8 
Hema goyal et 
al [59] (n=140) 90  61.4 40 
Current study 
(n=100) 91 52 57 35 
 
On physical examination, the most common finding was palor which 
was found in 97% of patients as opposed to other studies by Gayathri et al [55], 
Pereira & Dias et al[61], Majed momin et al [62] where palor was present in 
100% of patients. In our study three of the them were diagnosed to have 
dengue had their haemoglobin was in the range of 11-12g/dl. The second most 
common finding was splenomegaly(27%), hepatomegaly(15%) and 
icterus(11%) which was comparable to other studies conducted by Gayathri et 
al [55], Pereira & Dias et al[61], Majed momin et al [62] and Bhaskar B. 
Thakkar et al[64]. 
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TABLE 8.4: Comparison of studies on most common  
physical finding. 
Study 
Palor 
% 
Icterus 
% 
Splenomegaly 
% 
Hepatomegaly 
% 
Lymphadenopathy 
% 
Gayathri et al 
[55] (n=104) 
100 3.82 35.5 26.9 0.98 
Bhaskar B. 
Thakkar et 
al[64] (n=100) 
100 11 23 17 3 
Pereira & Dias 
et al [61] 
(n=80) 
100 6.2 32.5 20 7.5 
Majed momin 
et al [62] 
(n=150) 
100 10.6 36.6 10.6 4.6 
Current study 97 11 27 15 3 
 
Megaloblastic anaemia was found to be the most common etiology of 
pancytopenia in our study (37%) which was comparable to other studies in 
different regions of India by Dubey et al [60], Vaddatti Tejeswini et al [65], 
Neha Sharma et al [56], Patel et al [67], Gayathri et al [55], Bhaskar B. 
Thakkar et al[64], Pereira & Dias et al [61] and Majed momin et al [62]. 
However Studies by Dasgupta et al [66] conducted in kolkata, Santra G et 
al[70] and international agranulocytosis & aplastic anaemia study group in 
Israel & Europe[71] found aplastic anemia to be the most common etiology. 
Among the megaloblastic anaemia, the male to female ratio was 1.3:1 
and 29.7% were found to consume  vegetarian diet which may be responsible 
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for the deficient state. Among the male cases of megaloblastic anaemia, 42% 
were either alcoholic or smoker or both. 
Almost all patients of megaloblastic anemia presented with easy 
fatigueability (100%), fever was  the next common presenting complaint 
(48.6%) and 13.5% of these patients had some bleeding manifestation which 
was comparable to other studies by Hema goyal et al [59, Neha Sharma et al 
[56], Patel et al [67], Gayathri et al [55], Bhaskar B. Thakkar et al[64]. 
In the peripheral smear study, 76% of the patients showed macrocytosis 
with MCV>100, hypersegmented neutrophils was found in 90% and 74% of 
patients had LDH of >500 comparable to other studies by Para R et al [57], 
Eivazi-ziaei J et al [58], Tilak et al[3] , Khunger et al[15] and Ishtiaq et al[68]. 
Most of the megaloblastic anemia in our study had Vitamin B12 
deficiency alone (59.4%), 18.9% had folate deficiency alone and 16.2% had 
both vitamin B12 and Folate deficiency. Similar results were shown in the 
study done by Aziz et al[69]. 
Bone marrow study was deferred in most of the cases of megaloblastic 
anemia since most of the cases were diagnosed on history, examination, 
peripheral smear and vitamin B12 and folate analysis. Bone marrow study may  
show typical megaloblasts with sieved chromatin and asynchronic nuclear 
cytoplasmic ratio. 
In almost all age group in our study, megaloblastic anemia was found to 
be the major cause of of pancytopenia and were found to have some deficient 
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state. This reflects on the nutrititional status as an important cause of 
pancytopenia in our society. 
Aplastic anaemia was found to be the 2nd most common cause of 
pancytopenia in our study and comprised of 24% of cases with a male to 
female ratio of 1.1:1. Some other studies conducted in India by Dasgupta et al 
[66] and  Santra G et al[70] and international agranulocytosis & aplastic 
anaemia study group in Israel & Europe[71] found aplastic anaemia to be the 
most common etiology of pancytopenia. 
The incidence was higher in the age group >50 years(45.8%) and <20 
years(20.8%) and reflects on the bimodal age distribution of aplastic 
anemia[27], although it can be found in all age groups. Most of them presented 
with easy fatigueability(87.5%), bleeding manifestation(58.3%) and 
fever(54.1%). 
A 15 year old female had microcephaly, bifid thumbs, short stature and 
cafe-au-lait spots with bone marrow study showing hypoplasia. She was 
subsequently diagnosed as Fanoni anaemia. 
A 21 year old male presented with fever, shortness of breath, cough, 
redness of right eye and increased pigmentation of palms and soles for 2 weeks. 
On further history, he admits that he was abused with glue sniffing(dendrite) 
for 8 years and stagbond(toluene) for 1 month. On evaluation he was found to 
have low vitamin B12 and low cortisol with bone marrow study showing 
hypocellularity and atypical blastoid cells. He was then diagnosed as Toulene 
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induced hypoplasia and megaloblastic anaemia as the cause of pancytopenia. 
Thus such addiction histories are important to ask when the diagnosis is in 
doubt. 
Hypersplenism was the 3rd  most common etiology in our study(13%) 
with a mean age of 40.6 years and male to female ratio of 1.6:1. Most of them 
had  chronic liver disease(CLD) with portal hypertension(61%). Two cases 
were found to be HCV positive and 1 case HBV positive as the cause for CLD 
while the rest were ethanol related CLD. Extrahepatic portal vein obstruction 
(EHPVO) was found in 17% as the  cause of hypersplenism. Two female cases 
had non cirrhotic portal fibrosis(NCPF) and both of them has massive 
splenomegaly. 
This findings in contrast to earlier studies done by Hamid GAet al[72] 
and Kale Pet al [73] where they found hypersplenism as the most common 
cause for pancytopenia. Since those studies were done more than a decade ago, 
the better diagnosis and treatment of Malaria and Kala azar might have lead to 
the decreased incidence of these diseases in our study. 
The incidence of myelodysplastic syndrome is 6% in our study . Most of 
the patients are above 50 years . Hyposegmented neutrophils were seen in the 
peripheral smear of two patients with MDS. Diagnosis was confirmed by bone 
marrow study showing hypercellularity with abnormal cells. In these patients 
malignancy, monoclonal gammopathies were ruled out by appropriate 
85 
 
investigations. Serum folate and vit B12 levels were normal in all the patients 
with MDS in our study. 
Three patients were diagnosed to have SLE out of which one was a male 
patient. He presented with musculoskeletal and mucocutaneous features with  
malar rash, joint pain, oral ulcer and alopecia. He was subsequently found to 
have Lupus Nephritis of Grade 5. Thus haematological abnormality such as 
pancytopenia in male SLE should be evaluated further for renal involvement. 
Both the female cases in our study did not have renal involvement. 
Acute leukemia was diagnosed in 5 cases in our study. 3 patients had 
AML and 2 case ALL. This in contrast to other studies done in western country 
and Europe where acute leukemia as the most common etiology of 
pancytopenia-Weinzieri EP et al[74], Imbert et al[76]. 
Tropical infections such as dengue(4%) and malaria(4%) were also 
diagnosed in our study. All the cases of malaria were positive for vivax 
malariae. A study conducted in Pakistan by Tareem SM et al[75] found malaria 
as the most common etiology of pancytopenia. Thus these infections should 
also be kept in mind while dealing with pancytopenia cases especially in 
endemic areas. 
Immunocompromised states such as with HIV infection were found in 2 
cases. One patient had disseminated TB with bone marrow involvement. He 
eventually succumbed to sepsis and expired. This explains the seriousness of 
pancytopenia in such patients. 
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CONCLUSION 
• In India, megaloblastic anaemia was found to be the most common 
etiology for pancytopenia according to several studies done in different 
parts of the country. 
• Similarly  in our study, megaloblastic anaemia was found to be the most 
common cause for pancytopenia. 
• Most of them had either Vitamin B12 or Folate deficiency or both, thus 
reflecting the poor nutritional status of a developing country as India. 
This issue needs to be addressed so that the incidence of pancytopenia 
and thus its complications can be prevented with simple measures like 
dietary advice and timely supplementation. Also in our study, males 
tends to be affected more than females which could be due to the reason 
that most of them had ethanol abuse and its related CLD which may 
contribute to the deficient state. 
• The diagnosis and high index of suspicion of these cases can be made 
when a patient presents with easy fatigueability, fever or bleeding 
manifestation with hepatomegaly or splenomegaly or both and  
peripheral smear study showing macrocytosis and hypersegmented 
neutrophils with  decreased serum Vitamin B12 and folate assays. In 
such cases bone marrow studies can be deferred and can be treated with 
hematinics(Vitamin B12/Folate) with close haematological follow up. 
• Aplastic anaemia was the 2nd most common etiology in our study with 
slight male preponderance. The disease was found to be bimodal in 
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distribution. Blood counts were very low in such cases and all had 
hypoplastic marrow. Secondary cause  of aplasia such as exposure to 
drugs and chemicals like toluene  should be always sought for before 
labelling as primary disease. 
• Hypersplenism is another important  cause in our study. Chronic liver 
disease with portal hypertension was the major contributing factor. 
• Myelodysplastic syndrome should be suspected in elderly population 
with unexplained anaemia with pancytopenia. Bone marrow should be 
done to rule out malignancy. 
• Tropical infections such as dengue and malaria should always be ruled 
out especially in endemic areas. 
• Additional tests such as ANA, viral studies etc. should be considered 
when diagnosis is in doubt after ruling out the most common causes.  
• As our study also found megaloblastic anaemia as the most common 
cause comparable to other studies in different parts of our country, we 
may conclude that a major cause of pancytopenia in our country can be 
prevented and treated. 
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LIMITATION OF STUDY 
• The study group was small and was done in patients admitted to tertiary 
care hospital and thus the exact number and etiology in the general 
population cannot be assessed. 
• Some investigations such as intrinsic factor and some viral studies were 
not done to search for the cause of pancytopenia. 
• Trephine biopsy evaluation was not done in all patients. Therefore more 
definitive evaluation of cellularity and exclusion of focal lesions could 
not be done. 
• Follow up of patients was not done and so response to therapy could not 
be assessed. 
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PROFORMA 
1. Name: 
2. Age: 
3. Sex: 
4. Ip No: 
5. Symptoms 
a. Easy Fatigueability 
b. Fever 
c. Bleeding Manifestation 
d. Bone Pain 
e. Night Sweats 
f. Weight Loss 
g. Pruritus 
h. Others 
6. Dietary Habits: 
7. Smoking Status: 
8. Alcohol Consumption: 
9. Treatment History: 
10. Intake Or Exposure To Potential Toxic Chemical Agents Or Drugs 
11. Radiation Exposure 
12. Clinical Examination 
a. Pallor  
b. Icterus 
c. Hepatomegaly 
d. Splenomegaly 
e. Lymphadenopathy 
f. Sternal Tenderness 
g. Gum Hypertrophy 
h. Other Signs 
13. Investigations 
a. CBC 
i. Hb: 
ii. TLC: 
iii. Plateletes 
iv. MCV 
v. MCH 
vi. MCHC 
b. Peripheral Blood Smear 
c. LFT 
d. LDH 
e. Ultrasound Examination 
f. Bone Marrow Examination 
g. Other Investigation 
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PATIENT CONSENT FORM 
• Study Detail:“ PANCYTOPENIA : CLINICAL AND  ETIOLOGICAL PROFILE IN 
TERTIARY CARE HOSPITAL”  
• Study Centre: Rajiv Gandhi Government General Hospital, Chennai. 
• Patient’s Name: 
• Patient’s Age:  
• In Patient Number:  
• Patient may check (√) these boxes 
• I confirm that I have understood the purpose of procedure for the above study. I have 
the opportunity to ask question and all my questions and doubts have been answered 
to my complete satisfaction.❏  
• I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected.❏  
• I understand that sponsor of the clinical study, others working on the sponsor’s behalf, 
the ethical committee and the regulatory authorities will not need my permission to 
look at my health records, both in respect of current study and any further research 
that may be conducted in relation to it, even if I withdraw from the study I agree to 
this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this study.❏  
• I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to immediately 
inform the study staff if I suffer from any deterioration in my health or well being or 
any unexpected or unusual symptoms.❏  
• I hereby consent to participate in this study.❏  
• I hereby give permission to undergo detailed clinical examination and blood 
investigations as required.❏  
  
            
Signature of investigator                                                 Signature/Thumb impression  
   
Study investigator Name:                                                 Patient name and address:  
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SL. NO AGE SEX EASY FATIGUEABILITY FEVER BLEEDING TENDENCY BONE PAINS NIGHT SWEATS WEIGHT LOSS ANOREXIA DYSPNEA OTHERS DIET SMOKING ALCOHOL OTHER ADDICTION
1 16 M YES NO NO NO NO NO NO YES MIXED NO NO NO
2 24 M YES YES NO NO NO NO NO NO MIXED YES YES NO
3 55 F NO NO GUMS BLEED,MALENA NO NO NO NO NO MIXED NO NO NO
4 15 F YES YES NO NO NO NO NO NO MIXED NO YES NO
5 32 M NO YES NO NO NO NO NO NO LOOSE STOOLS MIXED YES YES NO
6 70 M YES NO HEMATEMESIS NO NO NO NO YES MIXED NO NO NO
7 44 M YES NO NO NO NO NO NO NO MIXED YES YES NO
8 60 M YES NO GUM BLEED NO NO NO NO NO MYALGIA MIXED NO NO NO
9 63 M YES NO NO NO NO NO NO YES MIXED NO NO NO
10 29 M YES YES NO NO NO YES YES YES ORAL ULCER MIXED NO YES NO
11 42 M YES NO NO NO NO NO NO NO JAUNDICE, VOMITING MIXED YES YES NO
12 46 M NO YES NO NO NO NO NO NO MIXED YES YES NO
13 37 M YES NO NO NO NO NO NO NO JAUNDICE MIXED YES YES NO
14 59 F YES YES NO NO NO NO NO YES MIXED NO NO NO
15 60 F YES NO NO NO NO NO NO YES MIXED NO NO NO
16 50 M NO YES NO NO NO NO NO YES  B/L LEG SWELLING VEG YES YES NO
17 38 M YES NO NO NO NO NO NO YES  JAUNDICE VEG NO YES NO
18 24 M YES YES NO ARTHRALGIA NO YES YES NO MALAR RASH, MYALGIA MIXED NO NO NO
19 33 M YES YES EPISTAXIS ARTHRALGIA NO NO NO NO MYALGIA MIXED NO NO NO
20 44 M YES NO NO NO NO NO NO NO VEG YES YES NO
21 39 M YES YES NO NO YES YES YES NO COUGH WITH EXP. MIXED YES NO NO
22 63 F YES NO NO NO NO NO NO YES MIXED NO NO NO
23 26 F YES YES NO NO NO NO NO NO MYALGIA MIXED NO NO NO
24 45 M YES NO HEMATEMESIS, MALENA NO NO YES YES YES MIXED YES YES NO
25 50 M YES YES NO NO NO NO NO NO JAUNDICE VEG NO NO NO
26 60 M YES NO NO NO NO YES YES NO MIXED NO NO NO
27 40 F YES NO NO NO NO YES YES NO VEG NO NO NO
28 52 F YES NO NO NO NO NO NO NO VEG NO NO NO
29 52 M YES NO NO NO NO NO YES NO MIXED YES YES NO
30 50 F YES YES NO NO YES NO NO NO MIXED NO NO NO
31 44 F YES YES NO NO NO NO NO NO VEG NO NO NO
32 53 M YES YES MALENA NO NO NO YES YES MIXED NO YES NO
33 19 M YES NO MALENA NO NO YES NO YES MIXED NO NO NO
34 38 F YES YES HEMATEMESIS, MALENA NO NO NO YES NO JAUNDICE MIXED NO NO NO
35 22 F NO NO  PETECHIAE ARTHRALGIA NO NO YES NO MIXED NO NO NO
36 40 F YES NO HEMATEMESIS, MALENA NO NO NO NO YES MIXED NO NO NO
37 45 F YES NO NO NO NO NO YES NO ANGULAR STOMATITIS VEG NO NO NO
38 38 M YES NO NO NO NO YES YES YES MIXED YES YES NO
39 48 M YES YES NO NO NO NO YES YES MIXED NO YES NO
40 21 F YES YES HEAVY MENS NO NO YES YES YES VEG NO NO NO
41 19 M YES YES GUM BLEED NO NO YES YES YES MIXED NO NO NO
42 40 F YES YES EASY BRUISABILITY NO NO NO NO YES MIXED NO NO NO
43 36 M YES NO MALENA NO NO YES YES NO MIXED YES YES NO
44 52 F YES NO NO NO NO NO NO NO MIXED NO NO NO
45 30 M YES YES NO NO NO NO NO NO MIXED NO NO NO
46 46 F YES YES NO NO NO YES YES NO JAUNDICE MIXED NO NO NO
47 42 M YES NO HEMATEMESIS, MALENA NO NO YES YES YES JAUNDICE MIXED YES YES NO
48 58 M YES YES NO NO NO NO YES YES MIXED YES YES NO
49 60 F YES NO NO NO NO YES YES NO MIXED NO NO NO
50 56 M YES YES NO NO YES YES YES YES MIXED YES YES NO
51 45 F YES YES GUM BLEED, EPISTAXIS NO NO NO NO YES MIXED NO NO NO
52 25 M YES NO MALENA NO NO NO YES NO MIXED NO NO NO
53 38 F YES YES NO ARTHRALGIA YES NO YES YES ALOPECIA MIXED NO NO NO
54 63 F YES NO NO NO NO NO YES YES MIXED NO NO NO
55 35 M YES YES NO NO NO NO YES NO JAUNDICE VEG NO NO NO
56 16 M YES YES GUM BLEED NO NO NO YES NO MIXED NO NO NO
57 37 F YES NO NO NO NO NO YES YES MIXED NO NO NO
58 38 M YES YES EASY BRUISE NO NO NO YES YES MIXED YES YES NO
59 28 M YES NO NO NO NO YES YES NO MIXED NO NO NO
60 36 F YES YES NO NO NO YES YES YES MYALGIA VEG NO NO NO
61 28 M YES YES EPISTAXIS ARTHRALGIA NO NO YES NO MYALGIA MIXED YES NO NO
62 18 F YES YES NO NO NO NO YES NO MIXED NO NO NO
63 65 F YES NO NO NO NO YES YES YES MIXED NO NO NO
64 17 F YES YES NO NO NO NO NO YES MIXED NO NO NO
65 34 M YES NO MALENA NO NO YES YES NO MIXED NO NO NO
66 55 F YES YES NO NO NO NO YES YES HYPERPIGMENTED KNUCKLES MIXED NO NO NO
67 68 M YES YES EPISTAXIS NO NO NO YES YES MIXED YES YES NO
68 17 M YES YES NO NO YES YES YES YES MIXED NO NO NO
69 28 M YES NO NO NO NO NO YES NO JAUNDICE MIXED YES NO NO
70 43 M YES YES NO NO NO NO NO YES MIXED NO NO NO
71 58 F YES NO NO NO NO NO NO NO MIXED NO NO NO
72 25 F YES YES HEAVY MENS NO NO YES YES NO GLOSSITIS, HYPERPIGMENTED KNUCKLES VEG NO NO NO
73 40 M YES YES HEMATEMESIS, MALENA NO NO YES YES YES JAUNDICE MIXED YES YES NO
74 50 F YES YES NO NO NO YES YES YES MIXED NO NO NO
75 48 M YES NO MALENA NO NO YES YES YES JAUNDICE MIXED YES YES NO
76 15 M YES YES NO NO YES NO YES YES MIXED NO NO NO
77 21 M YES YES NO NO NO NO NO NO MIXED NO NO NO
78 39 M YES NO MALENA NO NO YES YES YES JAUNDICE MIXED YES YES NO
79 58 M YES YES NO NO NO NO YES YES MIXED NO NO NO
80 35 M YES YES MALENA NO NO NO YES YES MIXED YES YES NO
81 37 M YES NO NO NO NO NO YES NO MIXED NO NO NO
82 58 M YES NO EASY BRUISABILITY NO NO YES YES YES MIXED NO YES NO
83 28 F YES YES NO NO NO YES YES YES MIXED NO NO NO
84 20 M YES YES EPISTAXIS NO NO NO NO YES VEG NO NO NO
85 52 F YES NO NO NO NO YES YES YES MIXED NO NO NO
86 39 F YES YES NO NO NO YES YES NO GLOSSITIC MIXED NO NO NO
87 31 M YES NO NO NO NO NO NO NO ANGULAR STOMATITIS MIXED YES YES NO
88 26 F YES YES EASY BRUISE, HEAVY MENS NO NO NO YES YES MIXED NO NO NO
89 33 F NO YES PETECHIAE NO NO NO NO NO MIXED NO NO NO
90 20 M NO YES NO NO NO NO YES NO MIXED NO NO NO
91 60 F NO NO NO NO NO NO YES YES ABDOMINAL DISTENSION MIXED NO NO NO
92 30 F YES NO EPIXTAXIS NO NO NO YES NO MIXED NO NO NO
93 40 F YES YES NO NO NO NO NO NO MIXED NO NO NO
94 48 F YES YES EASY BRUISABILITY ARTHRALGIA YES YES YES YES MIXED NO NO NO
95 21 M NO YES NO NO NO NO NO YES REDNESS OF EYES, HYPERPIGMENTATION OF PALMS & SOLESMIXED NO NO GLUE SNIFFER,STAFBOND
96 50 M YES YES NO NO NO NO YES YES VEG YES YES NO
97 60 F YES YES EASY BRUISABILITY NO NO YES YES YES MIXED NO NO NO
98 42 M YES NO MALENA NO NO YES YES YES MIXED YES YES NO
99 26 F YES YES NO NO NO NO NO NO MIXED NO NO NO
100 45 F YES YES NO NO NO NO YES YES HYPERPIGMENTED KNUCKLES MIXED NO NO NO
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SL. NO HB (g/dl) PCV TLC PLAT MCV (fl) MCH (pg) MCHC (g/dl) TB OT PT ALP TP RC LDH USG VIT B12 FOLATE
1 3.4 10 2000 13000 102.9 33.3 32.4 0.8 21 23 45 6.2 <0.5 % NORMAL
2 7.3 21 2700 79000 101.9 34.9 34.3 0.7 22 23 40 5.6 2% NORMAL 154 (DECREASED) >24 (NORMAL)
3 8.1 25 3700 21000 100 32.5 31.2 0.8 30 23 45 5.4 0.10% NORMAL
4 4 11 2500 21000 99 35 36 0.7 40 45 56 5.7 <0.5% NORMAL
5 11 30 2600 52000 85.2 30.7 36 0.5 21 23 30 5.4 1.90% NORMAL
6 5.4 15 1500 7000 96.7 34.4 35.5 0.7 30 32 38 6.2 0.20% NORMAL
7 3.3 11 2300 90000 109.1 22.9 29.3 0.7 25 26 40 5.5 1.80% NORMAL 500 (NORMAL) 3 (DECREASED)
8 7.4 20 1900 10000 81.6 30.3 37.2 0.6 12 21 23 5.4 0.30% 6976 NORMAL
9 4.6 12 3600 6000 93 24 37 0.9 23 30 33 5.9 0.20% NORMAL
10 6.8 19 1200 23000 76.7 27.3 35.6 0.8 33 35 45 5 0.60% SPLENOMEGALY
11 3.5 9 2700 40000 128 33 36.5 1.1 55 45 60 4.5 1.80% 1326 GR-1 FATTY LIVER 125 (DECREASED) <0.4 (DECREASED)
12 12 35 3100 57000 97.6 32 33.9 0.8 25 45 56 5.8 2% NORMAL
13 3.9 12 2700 27000 100.7 31.1 30.9 1.3 66 64 110 5.3 1.90% 4466 HSM 115(DECREASED) 3.9(DECREASED)
14 7.8 23 3400 28000 88.7 29.4 33.2 0.8 42 43 45 5.5 0.80% NORMAL 569(NORMAL) >24(NORMAL)
15 7.7 23 1900 24000 81.2 26.8 33 0.7 23 24 30 5.1 0.20% 203 NORMAL 425(NORMAL)
16 3.2 9 1500 7000 100 32.7 33 1.5 56 45 66 4.2 1.80% 1073 GR-1 FATTY LIVER 112(DECREASED) 2.5(DECREASED)
17 4.9 13 1800 47000 115.7 31.3 36.6 1.6 93 80 112 4.8 2% 1279 SPLENOMEGALY 133(DECREASED) 3.4(DECREASED)
18 10.9 30 1500 51000 96 30 36 1.5 66 60 123 4.8 1% NORMAL
19 11 30 3500 80000 90.6 30.5 35.5 0.7 25 26 54 6.1 1.90% GB WALL EDEMA
20 8.5 23 3800 90000 101 29 36.9 1.4 56 58 120 5.8 1.90% 754 GR-1 FATTY LIVER 358(NORMAL) 1.2(DECREASED)
21 7.6 24 2500 65000 80.5 25 31.6 1.1 46 45 84 5.4 0.40% HSM
22 6.2 25 2000 12000 85.3 25.6 24.8 0.8 24 22 56 5.2 0.20% NORMAL 256(NORMAL) NORMAL
23 10 30 3500 60000 86.8 31.5 33.3 1.2 43 41 54 5.6 1.50% HEPATOMEGALY
24 4.5 18 2200 39000 100 29.5 25 0.9 40 44 56 5.4 2.10% 690 SPLENOMEGALY 310(NORMAL) 4.8(DECREASED)
25 4.1 16 3300 28000 120 30.3 25.6 3 60 35 55 5.8 0.90% 2618 NORMAL 130 (DECREASED) >24(NORMAL)
26 6.2 19 2400 40000 91 28.3 32.6 1.8 45 45 54 5.6 0.70% 567 NORMAL
27 1.6 5 2200 4000 82.8 26 32 0.7 33 22 40 6.1 0.20% 134 MILD HEPATOMEGALY
28 7.2 21 3000 94000 110.2 33 34.5 0.6 31 26 43 5.1 0.90% 678 NORMAL 131(DECREASED) 11.3(NORMAL)
29 3.5 12 3100 79000 108.3 31.1 29.1 0.8 105 163 171 5.6 1.20% 1034 NORMAL 391(NORMAL) 3.9(DECREASED)
30 9.2 33 3200 120000 91.5 26.9 27.8 0.9 44 34 35 5.2 0.80% 778 NORMAL 245(NORMAL) 9.9(NORMAL)
31 5 21 2900 111000 114.2 31.2 23.8 0.6 44 53 34 5.4 0.90% 665 NORMAL 156(DECREASED) 6.1(NORMAL)
32 6.1 19 3600 40000 83.2 26.3 32.1 0.8 60 32 43 5.2 0.30% 135 NORMAL
33 5.1 16 2500 12000 88.6 29 31.8 0.6 22 25 35 6.1 0.10% 117 NORMAL 196(DECREASED) 23(NORMAL)
34 5.6 19 2600 86000 74.2 20.2 29.4 2 160 186 155 6.9 2.80% 209 CLD,SPLENOMEGALY
35 11 35 3400 20000 88.1 30.5 31.4 0.8 42 40 53 6 0.80% 156 NORMAL
36 4.1 18 2000 60000 87.5 22.6 22.7 1.1 43 39 69 5.9 0.20% 93 SPLENOMEGALY
37 7.1 21 3500 85000 112.2 32.4 33.8 0.5 15 35 45 5.5 0.60% 756 NORMAL 180(DECREASED) 10.2(NORMAL)
38 4.1 13 2000 95000 118.5 30.5 31.5 2.9 96 55 122 5.2 1.20% 927 HSM 181(DECREASED) 12.2(NORMAL)
39 4.8 14 2500 44000 93.8 30.6 34.2 0.8 32 44 51 6.2 0.90% 556 NORMAL 185(DECREASED) 7.2(NORMAL)
40 3.4 11 3400 6000 98.3 30.5 30.9 0.7 22 35 50 6.2 0.50% 125 NORMAL
41 3.9 12 1900 3000 91.5 28.4 32.5 0.9 35 29 49 5.4 0.60% 78 NORMAL
42 2.1 6 2700 3000 87.3 29.5 35 1.4 68 70 103 5.4 1.50% 156 HSM
43 9.7 32 3100 50000 105.1 28.2 30.3 1.1 85 70 114 6.1 1.20% 451 NORMAL 180(DECREASED) 8.1(NORMAL)
44 6.9 22 3100 69000 104.1 31.3 31.3 0.8 46 32 60 6 0.70% 661 NORMAL 220(NORMAL) 3.1(DECREASED)
45 11.4 34 3200 56000 87.5 25.9 33.5 0.6 15 23 34 6.4 2.10% 231 MILD HEPATOMEGALY
46 5.4 20 2200 76000 102.5 27.5 27 4.5 256 280 318 5.8 1.70% 184 HSM
47 7 25 2300 79000 74.5 20.5 28 5.2 167 90 280 4.8 1.90% 330 SPLENOMEGALY,CIRRHOSIS
48 8.4 24 3600 46000 96.1 28.4 33.4 1.9 42 39 64 4.8 1.00% 887 SPLENOMEGALY 356(NORMAL) 10.8(NORMAL)
49 6.5 23 3500 38000 97.9 25.1 28.2 0.9 68 70 82 5.7 0.90% 880 MILD SPLENOMEGALY 200(DECREASED) 7.8(NORMAL)
50 2.8 9 3500 110000 80.5 24.7 31.1 1.3 56 62 78 5.6 1.40% 265 NORMAL
51 3.8 12 2500 10000 93.1 29.9 31.6 0.7 42 31 38 5.6 0.50% 97 NORMAL
52 11.5 32 3200 88000 95.1 25.1 35.9 1.2 120 151 142 5.3 2.60% 135 SPLENOMEGALY
53 6 18 500 16000 87.8 26.9 33.3 2.8 130 176 155 5.4 0.70% 365 SPLENOMEGALY
54 9.5 33 3400 26000 110.4 35 28.7 0.8 23 35 52 6.2 0.20% 96 MILD SPLENOMEGALY
55 7.5 26 3300 130000 106.2 30.1 28.8 2.5 99 102 132 6.6 1.10% 1564 MILD SPLENOMEGALY 195(DECREASED) 10.3(NORMAL)
56 2.6 8 3300 12000 112 32.1 32.5 0.8 24 25 43 5.2 0.20% 102 NORMAL
57 5 16 3100 95000 108.2 31.2 31.2 1.1 45 55 62 5.9 1.30% 554 MILD HSM 340(NORMAL) 4.2(DECREASED)
58 4.9 14 2300 5000 98.1 31.1 35 0.5 50 30 89 5.8 0.10% 101 NORMAL
59 6.7 26 3300 66000 111 32.1 25.7 0.6 22 31 46 5 0.9.% 1280 NORMAL 200(DECREASED) 7.9(NORMAL)
60 6.6 21 2800 66000 113.2 32.5 31.4 1.5 45 56 52 6.3 0.8.% 1230 HSM 155(DECREASED) 3.4(DECREASED)
61 10.1 25 3400 9000 88.2 29.8 35.7 0.9 26 22 113 6.8 1.50% 211 GB EDEMA
62 2.2 10 2000 48000 106.3 32 22 0.7 35 36 55 5.1 0.70% 864 HSM 142(DECREASED) 5.6(LOW NORMAL)
63 4.6 18 2600 128000 67.8 18 25.5 0.6 23 31 34 5.6 0.90% 890 NORMAL
64 2.9 9 800 6000 125 33 32.2 3.9 88 85 86 6 2.50% 1720 NORMAL 140(DECREASED) 6.5(NORMAL)
65 8.8 27 3800 85000 87.5 28.1 32.5 0.9 157 159 205 5.6 2.20% 220 SPLENOMEGALY
66 3.6 18 2900 105000 95.6 27.2 20.1 2.8 40 33 45 5.7 0.60% 670 MILD SPLENOMEGALY 191(DECREASED) 10.2(NORMAL)
67 3.3 10 1600 3000 100 32.6 33 0.8 19 22 35 6.5 0.20% 120 NORMAL
68 7.4 23 500 18000 88.5 27.3 32.1 0.8 78 66 65 4.9 1.40% 187 HSM, LN +VE
69 6.8 20 3000 87000 105.1 31.9 34 1.8 66 76 105 5.9 0.70% 459 MILD HEPATOMEGALY 196(DECREASED) 6.9(NORMAL)
70 5.4 19 1200 17000 96.8 31.5 28.4 1.3 44 40 58 5 0.10% 113 NORMAL
71 6.9 21 3400 80000 101 32 32.8 1 40 38 70 5.4 1.40% 550 NORMAL 189(DECREASED) 9.3(NORMAL)
72 9.8 28 2600 8000 93.5 22.7 35 0.9 56 58 64 5.2 1.80% 173 HSM
73 10.2 33 3400 60000 82.5 25.1 30.9 4.5 189 200 250 5 2.50% 230 SPLENOMEGALY
74 6.7 20 2900 80000 105.1 31.2 33.5 0.8 25 32 45 5.7 1.00% 980 NORMAL 201(DECREASED) 6.2(NORMAL)
75 9.2 29 1800 26000 87.4 26.5 31.5 5.6 256 60 175 4.6 2.30% 230 SPLENOMEGALY,CIRRHOSIS
76 5.1 16 4000 98000 91.1 28.9 31.5 1 35 46 50 4.9 1.50% 145 HEPATOMEGALY
77 6.3 27 1700 51000 77.5 23.4 26.5 0.7 45 41 32 5.9 1.90% 765 NORMAL 290(NORMAL) 4.1(DECREASED)
78 3.8 15 3800 8000 81.5 27.9 25.3 6.5 235 156 285 4.8 2.50% 176 SPLENOMEGALY
79 2.9 9 1500 10000 122.2 40.3 32.2 1.1 32 23 40 5.9 0.30% 96 NORMAL
80 4.3 16 3400 120000 108.5 29.5 28.6 0.9 83 92 45 5.3 0.70% 354 MILD HEPATOMEGALY 184(DECREASED) 10.4(NORMAL)
81 5.7 19 2800 33000 111.8 26.8 30 0.5 44 50 45 5.6 0.80% 478 NORMAL 231(NORMAL) 9.4(NORMAL)
82 5.3 23 2500 112000 73.5 18.4 23.7 0.9 44 45 56 5.5 1.10% 378 SPLENOMEGALY
83 10.3 30 2200 90000 88.5 28.6 34.3 0.7 35 30 44 4.9 1.20% 235 NORMAL
84 3.6 10 2000 8000 79.5 28 34.7 0.8 88 95 105 5.3 0.40% 119 NORMAL
85 3.3 11 2300 4000 112.3 32.1 30.8 0.9 23 24 36 5.2 0.60% 963 NORMAL 440(NORMAL) 3.4(DECREASED)
86 7.5 28 3300 76000 119.5 33.4 28.4 0.8 33 46 55 5.6 0.90% 845 NORMAL 162(DECREASED) 6.4(NORMAL)
87 3.9 13 3200 36000 127.3 33.5 30 0.6 25 35 45 4.9 1.00% 289 NORMAL 165(DECREASED) 11.11(NORMAL)
88 2.2 8 1200 10000 82.3 26.4 27.5 1.2 33 35 44 5.6 0.20% 156 NORMAL
89 11.2 35 3900 20000 88.9 25.4 29.4 0.5 40 41 50 6.2 1.50% 112 NORMAL
90 10.9 33 3800 98000 91.2 28.4 33 0.9 49 40 125 6.5 1.50% 124 MILD SPLENOMEGALY
91 7.8 25.7 3600 88000 80.3 24.4 30.4 0.8 26 13 96 6 2.40% 98 CLD, GROSS ASCITES
92 8.2 29.5 2000 35000 73.6 20.4 27.8 0.8 29 23 97 6.4 1% 86 MASSIVE SPLENOMEGALY
93 9.7 31 3300 30000 107.5 31 31.7 1 134 155 106 5.2 0.50% 125 NORMAL
94 3.3 11 600 1000 91.1 28.4 30 0.8 35 40 45 4.9 1.50% 201 HSM
95 8.8 26 400 2000 92.3 30.7 33.2 1.5 77 72 62 6.5 0.90% 150 NORMAL 182(DECREASED) >24(NORMAL)
96 4.2 15 3000 8000 105.2 25 28 1.6 130 89 150 5.3 1.00% 1156 CLD 190(DECREASED) 3.0(DECREASED)
97 7.3 22 2000 15000 93 30.2 32.3 0.5 16 19 22 6.1 0.20% 118 NORMAL
98 3 9 1700 60000 93.5 29.1 31.3 3.8 256 345 330 4.6 1.40% 196 SPLENOMEGALY, CIRRHOSIS
99 10 33 3300 60000 90.1 25.9 30.3 0.7 12 20 40 6.5 2.10% 90 NORMAL
100 4 13 3500 120000 88.2 28.4 30.7 0.7 23 33 40 6 0.70% 789 NORMAL 200(DECREASED) 9.4(NORMAL)
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SL. NO PERIPHERAL BLOOD SMEAR FEVER PROFILE HIV VIRAL MARKERS OTHERS
1 MCHA/ MILD LEUCOPENIA/THROMBOCYTOPENIA: PCP NEG NEG NEG
2 MACROCYTIC ,ANISO, MACROOVALOCYTES/ LEUCO, HYPERSEGMENTED NEUTROPHILS/ ADEQUATE PLAT, CLUMPS +VE NEG NEG NEG
3 MCHA/LYMPHOCYTOSIS/ TCP: BICYTOPENIA NEG NEG NEG
4 SEVERE MCHA, ANISOPOIKILOCYTOSIS, PENCIL CELLS, TEAR DROP CELLS/ LEUCOPENIA/ TCP: PCP NEG NEG NEG
5 NCNC/NORMAL WBC/TCP 75000/ P.VIVAX TROPHOIZES +VE RING FORMS  P.VIVAX + NEG NEG
6 MCHA/LEUCOPENIA/TCP: PCP NEG NEG NEG
7 MACROCYTIC ANEMIA ,ANISO, MACROOVALOCYTES, TEAR DROP +VE/ LEUCOPENIA/ TCP, SINGLE: PCP NEG NEG NEG
8 MCHA/ DECREASE, MATURE/ TCP: PCP MSAT 2+ NEG NEG
9 MCHA,NCNC/ LYMPHOCYTOSIS/ TCP, SINGLE: BICYTOPENIA NEG NEG NEG
10 MICRO,MACRO,HYPO,ANISOPOIKILO,TEAR DROP, ELLIPTO,PENCIL SHAPED/ LEUCO/ TCP: PCP NEG NEG NEG
11 MCHA/LEUCOPENIA/PLATELETES ADEQUATE, CLUMPS: BICYTOPENIA NEG NEG NEG
12 NCNC/NORMAL WBC/TCP 85000/ P.VIVAX TROPHOIZES +VE RING FORMS P.VIVAX + NEG NEG
13 DIMORPHIC ANEMIA/ LEUCOPENIA, LYMPHOCYTE PREPONDERANCE/ TCP: DIMORPHIC ANEMIA, LEUCOPENIA,TCP NEG NEG NEG
14 NCNC/NORMAL WBC, LYMPHOCYTES 40%, ATYPICAL LYMP>10%/TCP: ?ITP/APLASTIC ANEMIA NEG NEG NEG
15 MCHA/LEUCOPENIA/TCP: PCP NEG NEG NEG
16 MCHA, ANISOPOIKILOCYTOSIS, TEAR DROP/LEUCOPENIA/TCP: PCP NEG NEG NEG
17 MCHA, ANISOPOIKILOCYTOSIS, TEAR DROP/LEUCOPENIA/TCP: PCP NEG NEG NEG
18 NCNC/LEUCOPENIA/TCP: BICYOPENIA MSAT 2+ NEG NEG ANA, dsDNA +VE
19 NCNC/NORMAL WBC/TCP: THROMBOCYTOPENIA DENGUE IgM +VE NEG NEG
20 MACROCYTIC/LEUCPENIA/TCP: PCP NEG NEG NEG
21 MCHA/LEUCOPENIA/TCP: PCP NEG POSITIVE NEG
22 MCHA/LEUCOPENIA/TCP: PCP NEG NEG NEG
23 NCNC/NORMAL WBC/TCP 66000/ P.VIVAX TROPHOIZES +VE RING FORMS P.VIVAX + NEG NEG
24 MACROCYTIC/LEUCPENIA/TCP: PCP NEG NEG NEG
25 MACROCYTIC ,ANISO, MACROOVALOCYTES/ LEUCO, HYPERSEGMENTED NEUTROPHILS/ ADEQUATE PLAT, CLUMPS +VE NEG NEG NEG
26 MCHA, ANISOPOIKILOCYTOSIS/LEUCOPENIA, OCC ATYPICAL CELLS/TCP, GIANT PLAT: PCP NEG NEG NEG
27 SEVERE MCHA, ANISOPOIKILOCYTOSIS/ LEUCOPENIA/TCP: PCP NEG NEG NEG
28 NCNC, MACROCYTIC, ANISOPOIKILOCYTOSIS/HYPERSEGMENTED NEUTROPHILS NEG NEG NEG
29 MACROCYTES, HYPERSEGMENTED NEUTROPHILS NEG NEG NEG
30 NCNC,MACROCYTIC, ANISOPOIKILOCYTOSIS, ERYTHROBLAST/ HYPERSEGMENTED NEUTROPHILS/TCP, NEG NEG NEG
31 MACROCYTES,ERYTHROBLAST, ANISOPOIKILOCYTOSIS/HYPERSEGMENTED NEUTROPHILS/TCP,CLUMPS: PCP NEG NEG NEG
32 MCHA/LEUCOPENIA/TCP: PCP NEG NEG NEG
33 NCHC/LEUCOPENIA/TCP: PCP NEG NEG NEG
34 MCHA NEG NEG NEG
35 NCNC/LEUCOPENIA, LYMPHOPENIA/TCP: BICYTOPENIA DENGUE IgM +VE NEG NEG
36 MCHA/LEUCOPENIA/TCP: PCP NEG NEG NEG PORTAL DOPPLER PHT
37 MACROCYTES,ERYTHROBLAST, ANISOPOIKILOCYTOSIS/HYPERSEGMENTED NEUTROPHILS/TCP,CLUMPS: PCP NEG NEG NEG
38 MACROCYTES,ANISOPOIKILOCYTOSIS/HYPERSEGMENTED NEUTROPHILS/TCP: BICYTOPENIA NEG NEG NEG
39 MACROCYTIC, ANISOPOIKILOCYTOSIS/HYPERSEGMENTED NEUTROPHILS/TCP: PCP NEG NEG NEG
40 MCHA/LEUCOPENIA/TCP: PCP NEG NEG NEG
41 MCHA/LEUCOPENIA/TCP: SEVERE PANCYTOPENIA NEG NEG NEG
42 MYELOBLAST +VE NEG NEG NEG
43 NCNC, MACROCYTIC, ANISOPOIKILOCYTOSIS/HYPERSEGMENTED NEUTROPHILS/ TCP, CLUMPS +VE: PCP NEG NEG NEG
44 MACROCYTES, ANISOPOIKILOCYTOSIS/HYPERSEGMENTED NEUTROPHILS/TCP: PCP NEG NEG NEG
45 NCNC/MILD LYMPHOCYTOSIS NEG NEG NEG
46 MCHA/LEUCOPENIA/CLUMPS NEG NEG ANTI HCV +VE
47 MCHA/LEUCOPENIA/TCP: PCP NEG NEG NEG
48 MCHA, TARGET CELLS NEG NEG NEG
49 MACROCYTIC, ANISOPOIKILOCYTOSIS/HYPERSEGMENTED NEUTROPHILS/TCP: PCP NEG NEG NEG
50 MCHA NEG POSITIVE NEG
51 MICRO/LEUCOPENIA/TCP: PCP NEG NEG NEG
52 MCHA, NORMO RBC, RETICULOCYTOSIS NEG NEG NEG PORTAL DOPPLER EHPVO
53 MCHA NEG NEG NEG ANA, dsDNA +VE
54 NCNC, MILD ANISOPOIKILOCYTOSIS, TEAR DROP CELLS/ LEUCOPENIA/TCP: PCP NEG NEG NEG
55 NORMO, MACROCYTIC,ANISOPOIKILOCYTOSIS, ERYTHROBLAST/HYPERSEGMENTED NEUTROPHILS/TCP: BICYTOPENIA NEG NEG NEG
56 MICRO,MACRO,HYPO,ANISOPOIKILOCYTOSIS/LEUCOPENIA/TCP: PCP NEG NEG NEG
57 MACROCYTIC, ERYTHROBLAST/HYPERSEGMENTED NEUTROPHILS/TCP: BICYTOPENIA NEG NEG NEG
58 MCHA/LEUCOPENIA/TCP: PCP NEG NEG NEG
59 MACROCYTIC, ANISOPOIKILOCYTIC/LEUCOPENIA: NEG NEG NEG
60 ANISOPOIKILOCYTOSIS/HYPERSEGMENTED NEUTROPHILS/TCP: PCP NEG NEG NEG
61 NCNC/RELATIVE LYMPHOCYTOSIS/TCP DENGUE IgM +VE NEG NEG
62 ANISOPOIKILOCYTOSIS/HYPERSEGMENTED NEUTROPHILS/TCP: PCP NEG NEG NEG
63 GROSS MCHA/LEUCOPENIA,ATYPICAL CELLS/TCP: PCP NEG NEG NEG
64 MACROCYTIC, ANISOPOIKILOCYTOSIS/HYPERSEGMENTED NEUTROPHILS/TCP: PCP NEG NEG NEG
65 MCHA, TARGET CELLS, RETICULOCYTOSIS NEG NEG NEG
66 MICROCYTIC, HYPOCHROMIC,NORMOCYTIC,ANISOPOIKILOCYTOSIS,TEAR DROP CELLS NEG NEG NEG
67 MCHA NEG NEG NEG
68 MCHA/LEUCOPENIA, BLASTS +VE/TCP NEG NEG NEG
69 MACROCYTIC,ANISOPOIKILOCYTOSIS,TEAR DROP CELLS/HYPERSEGMENTED NEUTROPHILS/TCP: PCP NEG NEG NEG
70 SEVERE MCHA, ANISOPOIKILOCYTOSIS/ LEUCOPENIA/TCP: PCP NEG NEG NEG
71 MACROCYTIC,ANISOPOIKILOCYTOSIS,ERYTHROBLAST/HYPERSEGMENTED NEUTROPHILS/TCP: PCP NEG NEG NEG
72 MACROCYTES/LEUCOPENIA, MYELOID BLAST+ve/TCP: BICYTOPENIA NEG NEG NEG
73 MICROCYTIC,HYPOCHROMIC, RETICULOCYTOSIS/LEUCOPENIA/TCP: PCP NEG NEG ANTI HCV +VE
74 POIKILOCYTOSIS/HYPERSEGMENTED NEUTROPHILS/TCP NEG NEG NEG
75 MCHA NEG NEG NEG
76 MYELOID BLAST 85% NEG NEG NEG
77 ANISOPOIKILOCYTOSIS/HYPERSEGMENTED NEUTROPHILS,LYMPHOCYTOSIS/TCP NEG NEG NEG
78 MCHA,TARGET CELLS, RETICULOCYTOSIS NEG NEG HBSAg +VE
79 MACROCYTIC/LEUCOPENIA NEG NEG NEG
80 MILD ANISOPOIKILOCYTOSIS/HYPERSEGMENTED NEUTROPHILS/PLATELETE CLUMPS +VE NEG NEG NEG
81 MACROCYTIC, FEW TARGET CELLS,ANISOPOIKILOCYTOSISI/HYPERSEGMENTED NEUTROPHILS/TCP NEG NEG NEG
82 MICROCYTIC,HYPOCHROMIC,NORMOCHROMIC RBC NEG NEG NEG
83 MICROCYTIC,HYPOCHROMIC,NORMOCHROMIC RBC NEG NEG NEG
84 MCHA/LEUCOPENIA/TCP: PCP NEG NEG NEG ANA, dsDNA +VE
85 MACROCYTES, ANISOPOIKILOCYTOSIS NEG NEG NEG
86 ANISOPOIKILOCYTOSIS/HYPERSEGMENTED NEUTROPHILS/TCP: PCP NEG NEG NEG
87 MACROCYTES,ANISOPOIKILOCYTOSIS, ERYTHROBLASTS +ve/HYPERSEGMENTED NEUTROPHILS/TCP NEG NEG NEG
88 MCHA/LEUCOPENIA/TCP: PCP NEG NEG NEG
89 NORMOCYTIC/RELATIVE LYMPHOCYTOSIS/TCP DENGUE IgM +VE NEG NEG
90 NCNC/NORMAL WBC/TCP/ P.VIVAX TROPHOIZES +VE RING FORMS P.VIVAX + NEG NEG
91 NORMOCYTIC,MCHA/TCP NEG NEG NEG PV DOPPLER: PHT
92 MCHA,ANISOCYTOSIS,PENCIL SHAPED CELLS/LEUCOPENIA,MATURED/TCP: PCP NEG NEG NEG
93 MCHA/LEUCOPENIA/TCP: PCP NEG NEG NEG
94 BLASTS +ve, LEUCOPENIA/TCP NEG NEG NEG
95 MCHA,ANISOCYTOSIS/LEUCOPENIA,FEW EOSINOPHILS/TCP: PCP NEG NEG NEG
96 DIMORPHIC ANEMIA/ LEUCOPENIA,HYPERSEGMENTED NEUTROPHILS LYMPHOCYTE PREPONDERANCE/ TCP NEG NEG NEG
97 MCHA/LEUCOPENIA/TCP: PCP NEG NEG NEG
98 MCHA,ELLIPTOCYTOSIS NEG NEG NEG
99 NCNC/MILD LYMPHOCYTOSIS NEG NEG NEG
100 MICROCYTIC, HYPOCHROMIC,NORMOCYTIC,ANISOPOIKILOCYTOSIS,TEAR DROP CELLS NEG NEG NEG
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SL. NO BONE MARROW STUDY STOOL OCCULT BLOOD UGI ENDO
1 NEG NORMAL
2 NEG
3 BM BX: APLASTIC MARROW NEG NORMAL
4 BM BX: HYPOCELLULAR NEG
5 NEG
6 BMA: NO BLAST, BM BX: HYPOCELLULAR WITH TRILINEAGE HEMATOPOIESIS NEG
7 NEG
8 BM BX: HYPOPLASIA NEG
9 BM BX: HYPOPLASIA, NO E/O INFILTRATION NEG
10 BMA: HYPOCELLULAR, MEGAKARYOCYTES, MICROMEGAKARYOCYTES, MYELOID SERIES NORMAL: MEGALOBLASTIC ANEMIA WITH MDSNEG NORMAL
11 NEG NORMAL
12 NEG
13 BMA: ERYTHROID HYPERPLASIA/ HISTIOCYTES INCREASED/MEGALOBLASTIC NEG
14 BMA: HYPERCELLULAR, INCREASED IRON STORES, BM BX: HYPERCELLULAR, MOD GRANULOCYTIC HYPERPLASIA, MILD-MOD MEGALOBLASTIC CHANGENEG NORMAL
15 BM BX:ERYTHROID HYPERPLASIA, NEG
16 NEG
17 NEG
18 NEG
19 NEG
20 NEG
21 BM BX: GRANULOMATOUS INFLAMMATION NEG
22 BMA: HYPOCELLULAR NEG
23 NEG
24 POSITIVE PANGASTRITIS
25 NEG
26 HYPERCELLULAR, FRAGMENTED ERYTHROBLAST NEG
27 HYPOCELLULAR, REPLACED BY FAT CELLS NEG
28 HYPERCELLULAR, MEGALOBLASTIC NEG NORMAL
29 HYPERCELLULAR,MEGALOBLASTIC, LARGE MEGAKARYOCYTES NEG PANGASTRITIS, DUODENITIS
30 IMMATURE MYELOID BLASTS PRESENT NEG NORMAL
31 NEG NORMAL
32 HYPOCELLULAR, REPLACED BY FAT CELLS POSITIVE ANTRAL GASTRITIS
33 HYPERCELLULAR, MEGALOBLASTIC, ERYTHROID HYPERPLASIA, LARGE MEGAKARYOCYTES POSITIVE ANTRAL GASTRITIS
34 POSITIVE ESOPHAGEAL VARICES
35 NEG
36 POSITIVE ESOPHAGEAL VARICES
37 NEG
38 NEG PANGASTRITIS, DUODENITIS
39 NEG GASTRIC EROSIONS
40 HYPOCELLULAR, REPLACED BY FAT CELLS NEG
41 HYPOCELLULAR, REPLACED BY FAT CELLS NEG
42 LEUKEMIC BLASTS +VE NEG
43 POSITIVE PANGASTRITIS, DUODENITIS
44 NEG
45 NORMOCELLULAR, PRECURSORS NORMAL NEG
46 MILD TO MODERATE MEGALOBLASTIC CHANGES NEG ESOPHAGEAL VARICES
47 POSITIVE ESOPHAGEAL VARICES
48 HYPERCELLULAR, DYSERYTHROPOIETIC, ABNORMAL MEGAKARYOCYTES, RINGED SIDEROBLAST NEG
49 HYPERCELLULAR, LARGE MEKARYOCYTES + NEG NORMAL
50 HYPOCELLULAR,OCC MEGAKARYOCYTES WITH BARE NUCLEI, DYSERYTHROPOIESIS, DECREASE IN ERYTHROID AND MYELOID PROGENITOR CELLSNEG NORMAL
51 HYPOCELLULAR MARROW, REPLACED BY FAT NEG NORMAL
52 HYPERCELLULAR MARROW, NORMAL PRECURSORS POSITIVE ESOPHAGEAL VARICES
53 HYPOCELLULAR, FIBROSIS, DECREASED MYELOID PRECURSORS NEG NORMAL
54 HYPOCELLULAR, REPLACED BY FAT CELLS NEG
55 NEG NORMAL
56 HYPOCELLULAR, REPLACED BY FAT CELLS NEG NORMAL
57 NEG NORMAL
58 HYPOCELLULAR, REPLACED BY FAT CELLS NEG NORMAL
59 NEG GASTRIC EROSIONS
60 HYPERCELLULAR, MEGALOBLASTIC NEG NORMAL
61 NEG
62 HYPERCELLULAR, MEGALOBLASTIC NEG ATROPHIC GASTRITIS
63 HYPERCELLULAR,DYSERYTHROPOIETIC, BINUCLEATED ERYTHROID PRECURSOR, ABNORMAL MEGAKARYOCYTES NEG
64 HYPERCELLULAR,MEGALOBLASTIC, ERYTHROID HYPERPLASIA NEG NORMAL
65 POSITIVE ESOPHAGEAL & FUNDAL VARICES
66 HYPERCELLULAR, MEGALOBLASTIC, ERYTHROID HYPERPLASIA NEG
67 HYPOCELLULAR, REPLACED BY FAT CELLS NEG
68 LYMPHOID LEUKEMIC BLASTS PRESENT NEG
69 NEG PANGASTRITIS, DUODENITIS
70 HYPOCELLULAR MARROW, REPLACED BY FAT NEG
71 HYPERCELLULAR, MEGALOBLASTIC, METAMYELOCYTES +VE NEG NORMAL
72 HYPERCELLULAR, MEGALOBLASTIC NEG
73 POSITIVE ESOPHAGEAL VARICES
74 HYPERCELLULAR, MEGALOBLASTIC NEG NORMAL
75 POSITIVE ESOPHAGEAL VARICES
76 MYELOID LEUKEMIC BLAST NEG
77 NEG PANGASTRITIS
78 HYPERCELLULAR, NORMAL PRECURSORS POSITIVE ESOPHAGEAL & GASTRIC VARICES
79 HYPOCELLULAR MARROW, REPLACED BY FAT NEG NORMAL
80 POSITIVE EROSIVE GASTRITIS
81 NEG EROSIVE GASTRITIS
82 HYPERCELLULAR MARROW, RINGED SIDEROBLAST +ve, DYSPLASTIC NEG
83 HYPOCELLULAR MARROW NEG NORMAL
84 HYPOCELLULAR MARROW, REPLACED BY FAT NEG NORMAL
85 HYPERCELLULAR, MEGALOBLASTIC NEG NORMAL
86 NEG ATROPHIC GASTRITIS
87 NEG GASTRITIS
88 HYPOCELLULAR, REPLACED BY FAT CELLS NEG
89 NEG
90 NEG
91 NEG ESOPHAGEAL VARICES
92 NEG
93 HYPOCELLULAR, REPLACED BY FAT CELLS NEG
94 LYMPHOID LEUKEMIC BLASTS PRESENT NEG
95 HYPOCELLULAR, BONE MARROW HYPOPLASIA NEG
96 NEG
97 HYPOCELLULAR, REPLACED BY FAT CELLS NEG
98 POSITIVE ESOPHAGEAL VARICES, GASTRITIS
99 NORMOCELLULAR, PRECURSORS NORMAL NEG
100 HYPERCELLULAR, MEGALOBLASTIC, ERYTHROID HYPERPLASIA NEG
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SL NO. BONE MARROW STUDY DIAGNOSIS S. IRON S. FERRITIN
1 APLASTIC ANEMIA
2 MEGALOBLASTIC ANEMIA; VIT B12 DEF.
3 BM BX: APLASTIC MARROW APLASTIC ANEMIA
4 BM BX: HYPOCELLULAR FANCONI ANEMIA
5 P. VIVAX MALARIA
6 BMA: NO BLAST, BM BX: HYPOCELLULAR WITH TRILINEAGE HEMATOPOIESIS APLASTIC ANEMIA
7 MEGALOBLASTIC ANEMIA; FOLATE DEF.
8 BM BX: HYPOPLASIA APLASTIC ANEMIA
9 BM BX: HYPOPLASIA, NO E/O INFILTRATION APLASTIC ANEMIA
10 BMA: HYPOCELLULAR, MEGAKARYOCYTES, MICROMEGAKARYOCYTES, MYELOID SERIES NORMAL: MEGALOBLASTIC ANEMIA WITH MDSMDS/MEGALOBLASTIC ANEMIA
11 MEGALOBLASTIC ANEMIA; VIT B12 & FOLATE DEF.
12 P. VIVAX MALARIA
13 BMA: ERYTHROID HYPERPLASIA/ HISTIOCYTES INCREASED/MEGALOBLASTIC MEGALOBLASTIC ANEMIA; VIT B12 & FOLATE DEF, CLD WITH PHT
14 BMA: HYPERCELLULAR, INCREASED IRON STORES, BM BX: HYPERCELLULAR, MOD GRANULOCYTIC HYPERPLASIA, MILD-MOD MEGALOBLASTIC CHANGEM S
15 BM BX:ERYTHROID HYPERPLASIA, APLASTIC ANEMIA
16 MEGALOBLASTIC ANEMIA; VIT B12 & FOLATE DEF.
17 MEGALOBLASTIC ANEMIA; VIT B12 & FOLATE DEF.
18 SLE
19 DENGUE FEVER
20 MEGALOBLASTIC ANEMIA: FOLATE DEF.
21 BM BX: GRANULOMATOUS INFLAMMATION DISSEMINATED TB
22 BMA: HYPOCELLULAR APLASTIC ANEMIA
23 P. VIVAX MALARIA
24 HYPERSPLENISM
25 MEGALOBLASTIC ANEMIA: VIT B12 DEF.
26 HYPERCELLULAR, FRAGMENTED ERYTHROBLAST MDS 170 250
27 HYPOCELLULAR, REPLACED BY FAT CELLS APLASTIC ANEMIA
28 HYPERCELLULAR, MEGALOBLASTIC MEGALOBLASTIC ANEMIA: VIT B12 DEF. 250 185
29 HYPERCELLULAR,MEGALOBLASTIC, LARGE MEGAKARYOCYTES MEGALOBLASTIC ANEMIA:FOLATE DEF. 117 234
30 IMMATURE MYELOID BLASTS PRESENT ACUTE MYELOID LEUKEMIA 199 175
31 MEGALOBLASTIC ANEMIA: VIT B12 DEF. 211 197
32 HYPOCELLULAR, REPLACED BY FAT CELLS APLASTIC ANEMIA
33 HYPERCELLULAR, MEGALOBLASTIC, ERYTHROID HYPERPLASIA, LARGE MEGAKARYOCYTES MEGALOBLASTIC ANEMIA
34 HYPERSPLENISM, EHPVO, CLD 120 95
35 DENGUE FEVER
36 HYPERSPLENISM, NCPF
37 MEGALOBLASTIC ANEMIA: VIT B12 DEF. 256 195
38 MEGALOBLASTIC ANEMIA: VIT B12 DEF. 171 288
39 MEGALOBLASTIC ANEMIA: VIT B12 DEF. 345 256
40 HYPOCELLULAR, REPLACED BY FAT CELLS APLASTIC ANEMIA
41 HYPOCELLULAR, REPLACED BY FAT CELLS APLASTIC ANEMIA
42 LEUKEMIC BLASTS +VE ACUTE MYELOID LEUKEMIA
43 MEGALOBLASTIC ANEMIA: VIT B12 DEF. 231 340
44 MEGALOBLASTIC ANEMIA: FOLATE DEF./HYPOTHYROID 185 213
45 NORMOCELLULAR, PRECURSORS NORMAL VIRAL INDUCED PANCYTOPENIA
46 MILD TO MODERATE MEGALOBLASTIC CHANGES HYPERSPLENISM/CLD/HCV 95 154
47 HYPERSPLENISM, CLD, ETHANOL 138 98
48 HYPERCELLULAR, DYSERYTHROPOIETIC, ABNORMAL MEGAKARYOCYTES, RINGED SIDEROBLAST MDS 176 262
49 HYPERCELLULAR, LARGE MEKARYOCYTES + MEGALOBLASTIC ANEMIA,VIT B12 DEF., HYPOTHYROID 250 176
50 HYPOCELLULAR,OCC MEGAKARYOCYTES WITH BARE NUCLEI, DYSERYTHROPOIESIS, DECREASE IN ERYTHROID AND MYELOID PROGENITOR CELLSHIV INDUCED PA CYTOPENIA 79 55
51 HYPOCELLULAR MARROW, REPLACED BY FAT APLASTIC ANEMIA
52 HYPERCELLULAR MARROW, NORMAL PRECURSORS HYPERSPLENISM, EHPVO 87 98
53 HYPOCELLULAR, FIBROSIS, DECREASED MYELOID PRECURSORS SLE, CTD
54 HYPOCELLULAR, REPLACED BY FAT CELLS APLASTIC ANEMIA
55 MEGALOBLASTIC ANEMIA: VIT B12 DEF. 199 280
56 HYPOCELLULAR, REPLACED BY FAT CELLS APLASTIC ANEMIA
57 MEGALOBLASTIC ANEMIA, FOLATE DEF. 160 153
58 HYPOCELLULAR, REPLACED BY FAT CELLS APLASTIC ANEMIA
59 MEGALOBLASTIC ANEMIA, VIT B12 DEF. 163 251
60 HYPERCELLULAR, MEGALOBLASTIC MEGALOBLASTIC ANEMIA, VIT B12 & FOLATE DEF. 204 190
61 DENGUE
62 HYPERCELLULAR, MEGALOBLASTIC MEGALOBLASTIC ANEMIA: VIT B12 DEF. 168 176
63 HYPERCELLULAR,DYSERYTHROPOIETIC, BINUCLEATED ERYTHROID PRECURSOR, ABNORMAL MEGAKARYOCYTES MDS
64 HYPERCELLULAR,MEGALOBLASTIC, ERYTHROID HYPERPLASIA MEGALOBLASTIC ANEMIA: VIT B12 DEF. 234 170
65 HYPERSPLENISM, EHPVO 55 101
66 HYPERCELLULAR, MEGALOBLASTIC, ERYTHROID HYPERPLASIA MEGALOBLASTIC ANEMIA 134 156
67 HYPOCELLULAR, REPLACED BY FAT CELLS APLASTIC ANEMIA
68 LYMPHOID LEUKEMIC BLASTS PRESENT ALL
69 MEGALOBLASTIC ANEMIA: VIT B12 DEF. 180 284
70 HYPOCELLULAR MARROW, REPLACED BY FAT APLASTIC ANEMIA
71 HYPERCELLULAR, MEGALOBLASTIC, METAMYELOCYTES +VE MEGALOBLASTIC ANEMIA, VIT B12 DEF. 160 170
72 HYPERCELLULAR, MEGALOBLASTIC MEGALOBLASTIC ANEMIA, VIT B12 DEF.
73 HYPERSPLENISM, CLD, HCV
74 HYPERCELLULAR, MEGALOBLASTIC MEGALOBLASTIC ANEMIA, VIT B12 DEF.
75 HYPERSPLENISM, CLD, ETHANOL 65 90
76 MYELOID LEUKEMIC BLAST ACUTE MYELOID LEUKEMIA
77 MEGALOBLASTIC ANEMIA, FOLATE DEF. 235 305
78 HYPERCELLULAR, NORMAL PRECURSORS HYPERSPLENISM, CLD, HBV 75 105
79 HYPOCELLULAR MARROW, REPLACED BY FAT APLASTIC ANEMIA
80 MEGALOBLASTIC ANEMIA, VIT B12 DEF. 180 294
81 MEGALOBLASTIC ANEMIA 176 355
82 HYPERCELLULAR MARROW, RINGED SIDEROBLAST +ve, DYSPLASTIC MDS
83 HYPOCELLULAR MARROW SLE, CTD 87 189
84 HYPOCELLULAR MARROW, REPLACED BY FAT APLASTIC ANEMIA
85 HYPERCELLULAR, MEGALOBLASTIC MEGALOBLASTIC ANEMIA, FOLATE DEF. 176 188
86 MEGALOBLASTIC ANEMIA, VIT B12 DEF. 134 120
87 MEGALOBLASTIC ANEMIA, VIT B12 DEF. 175 299
88 HYPOCELLULAR, REPLACED BY FAT CELLS APLASTIC ANEMIA
89 DENGUE
90 P. VIVAX MALARIA
91 HYPERSPLENISM, CLD
92 NCPF
93 HYPOCELLULAR, REPLACED BY FAT CELLS APLASTIC ANEMIA
94 LYMPHOID LEUKEMIC BLASTS PRESENT ALL
95 HYPOCELLULAR, BONE MARROW HYPOPLASIA TOULENE INDUCED APLASIA, VIT B12 DEF.
96 MEGALOBLASTIC ANEMIA: VIT B12 & FOLATE DEF.
97 HYPOCELLULAR, REPLACED BY FAT CELLS APLASTIC ANEMIA
98 HYPERSPLENISM,CLD
99 NORMOCELLULAR, PRECURSORS NORMAL VIRAL INDUCED PANCYTOPENIA
100 HYPERCELLULAR, MEGALOBLASTIC, ERYTHROID HYPERPLASIA MEGALOBLASTIC ANEMIA 130 150
